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ABSTRACT 
 
GDNF family ligands (GDNF, neurturin, artemin and persephin), and mesencephalic 
astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic 
factor (CDNF) protect midbrain dopaminergic neurons that degenerate in Parkinson's 
disease. Each of the four homodimeric GDNF ligands binds a specific coreceptor GDNF 
family  receptor  ? (GFR?),  leading  to  the  formation  of  a  heterotetramer  complex,  which  
then interacts with receptor tyrosine kinase RET, the signalling receptor. The structure of 
the GDNF monomer has cystine knot topology, consisting of the heel and the finger 
domain. However, MANF and CDNF form a novel neurotrophic factor family with eight 
conserved cysteines, the receptors for which have not been identified. The present thesis 
describes the structural and biochemical characterization of the GDNF2-GFR?12 complex 
and the MANF and CDNF proteins. 
The crystal structure of the GDNF2-GFR?12 complex shows that ion-triple and 
hydrophobic interactions between the GDNF finger domain and the domain 2 of GFR?1 
are responsible for the complex formation, as in the artemin2-GFR?32 structure. Previous 
and current mutation data and comparison between GDNF-GFR?1 and artemin-GFR?3 
binding interfaces show that N162GFR?1, I175GFR?1, V230GFR?1, Y120GDNF and L114GDNF 
are the specificity determinants among different ligand-coreceptor pairs. 
As heparin or heparan sulphates have been suggested to influence GDNF signalling, the 
crystal structure of the GDNF2-GFR?12 complex was solved in the presence of the heparin 
mimic, sucrose octasulphate (SOS). The structure suggests that heparin interacts with a 
region R190-K202 within domain 2 of GFR?1, consistent with previous predictions. 
Mutating these residues on the GFR?1 surface, which are not in the GDNF binding region, 
affected RET phosphorylation. I could thus identify a putative RET binding region in 
domain 2 and 3 of GFR?1. The mutant and structural data suggest that the heparin and 
RET binding sites within GFR?1 overlap.  
The structural comparison of the GDNF2-GFR?12 and artemin2-GFR?32 complexes shows 
a difference in bend angle between the ligand monomers. This variation in bend angle of 
the ligand may affect the kinetics of RET phosphorylation. To confirm that the difference 
is not due to crystallization artefacts, I crystallized the GDNF2-GFR?12 complex without 
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SOS in different cell dimensions. The structure of the second GDNF2-GFR?12 complex is 
very similar to the previous one, suggesting that the difference between the artemin2-
GFR?32 and  GDNF2-GFR?12 complexes are intrinsic, not due to crystal packing. From 
the  comparison  of  eleven  GDNF and artemin  structures,  GDNF2 seems to be more bent 
and more flexible than artemin2, and this may be related to RET signalling. The 
differences appear to be due to increased curvature of the artemin fingers, which both 
increases the buried surface area in the monomer-monomer interface and changes the 
intermonomer bend angle.  
Finally, MANF and CDNF are bifunctional proteins with extracellular neurotrophic 
activity and ER resident cytoprotective role. The crystal structures of MANF and CDNF 
are presented here. Intriguingly, the structures of both the neurotrophic factors do not 
show structural similarity to any of previously known growth factor superfamilies; instead 
they are similar to saposins, the lipid-binding proteins. The N-terminal domain of MANF 
and CDNF contain conserved lysines and arginines on its surface, which may interact with 
negatively charged head groups of phospholipids, as saposins do. Thus MANF and CDNF 
may provide neurotrophic activities by interacting with a lipo-receptor. The structure of 
MANF shows a CXXC motif forming internal disulphide bridge in the natively unfolded 
C-terminus. This motif is common to reductases and disulphide isomerases. It is thus 
tempting to speculate that the CXXC motif of MANF and CDNF may be involved in 
oxidative protein folding, which may explain its cytoprotective role in the ER. 
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1.  LITERATURE REVIEW 
 
1.1 Neurotrophic factors 
Neurotrophic factors are small proteins that provide trophic (derived from the Greek 
?????, meaning "to nourish") events in neuronal cells. These secreted neurotrophic factors 
act by binding to the specific cell surface receptor(s) that signal the neuron to survive. 
Neurotrophic factors are important in the developing and mature nervous system. They 
influence cell proliferation, survival, differentiation, migration, axon and dendritic growth 
and synaptic plasticity. They play critical roles in complex behaviors including anxiety, 
depression (Vaidya and Duman, 2001), and learning (Mangina and Sokolov, 2006). 
Neurotrophic factors may provide treatment for a variety of neurological diseases including 
Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy and neuropathies. 
They can be given exogenously as pure proteins or through gene therapy (Lawlor and 
During, 2004), to prevent nerve cell death caused by various insults including nerve injury, 
brain trauma, and exposure to toxins. 
A number of trophic factors that exert survival-promoting effects in experimental models 
of nervous system injury and neurodegenerative diseases can be grouped into families 
based on homology of the trophic factors, receptors, and common transduction pathways. 
There are currently four families of trophic factors that are specific to the nervous system 
(Figure 1.1). Three of them, which include neurotrophins, neuropoietic cytokines and glial 
cell line-derived neurotrophic factor (GDNF) family, have been well characterized (for a 
review, see Butte, 2001). The fourth one consisting of mesencephalic astrocyte-derived 
neurotrophic factor (MANF, Petrova et al., 2003) and conserved dopamine neurotrophic 
factor (CDNF, Lindholm et al., 2007) has recently shown to have potent neurotrophic 
effects. These neurotrophic factor families promote the survival of dopaminergic neurons, 
and provide protective and restorative effects against neurodegeneration. The neurotoxins 
6-hydroxydopamine (6-OHDA) (Simon et al., 1974) and 1-methyl-4 phenyl-1,2,5,6-
tetrahydropyridine (MPTP) (Heikkila et al., 1984) are used in neurodegenerative models of 
rats and monkeys. To observe neuroprotective effects, trophic factor is injected before the 
toxin; whereas in neurorestoration, it is injected after the lesion is induced. A number of 
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other trophic factors also have survival promoting, protective and restorative effects on 
dopamine neurons in vitro and in vivo (Table 1).  
 
Figure 1.1 Neurotrophic factors. Abbreviations: NGF, nerve growth factor (neurotrophin-1); 
BDNF, brain-derived neurotrophic factor (neurotrophin-2); NT, neurotrophin; CNTF, ciliary 
neurotrophic factor; IL-6, interleukin-6; CT-1, cardiotrophin-1; GDNF, glial cell line-derived 
neurotrophic  factor;  GFL,  GDNF  family  of  ligands;  NRTN,  neurturin;  ARTN,  artemin;  PSPN,  
persephin; MANF, mesencephalic astrocyte derived neurotrophic factor; CDNF, conserved 
dopamine neurotrophic factor. 
The most studied neurotrophic factors form the neurotrophin family, consisting of nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
and neurotrophin-4/5 (NT-4/5) (Reichardt, 2006). Neurotrophins support various neuronal 
populations in the peripheral nervous system and the central nervous system (Huang and 
Reichardt, 2001). Nerve growth factor promoted the neurite growth of sympathetic neurons 
in chicken (Levi-Montalcini and Hamburger, 1951). BDNF was the first neurotrophin 
described to promote the survival and dopamine uptake of embryonic midbrain 
dopaminergic neurons in vitro (Hyman et al., 1991). It prevented neuronal death caused by 
6-OHDA (Spina et al., 1992).  Later other neurotrophins including NT-3 and NT-4 also 
showed survival promoting effects in dopaminergic neurons. Neurotrophins can bind two 
unrelated receptors: tropomyosin-related kinase (Trk A, Trk B, Trk C) and a common 
neurotrophin receptor p75NTR (Reichardt, 2006). Trks are tyrosine kinase receptors that 
stimulate the mitogen-activated protein kinase (MAPK) pathway, while p75NTR is a tumor 
necrosis factor receptor, and signals through an intracellular death domain to activate the 
cellular apoptosis machinery. Ligand binding is selective to different Trks, whereas all 
neurotrophins bind to p75NTR. 
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Table 1. Other growth factors with effects on dopaminergic neurons.  
 
Trophic Factor Reference (for 
trophic activities)  
Neuroprotection 
model (Ref.) 
Neurorestoration model 
(Ref.) 
Erythropoietin (EPO) Studer et al., 2000 6-OHDA rat (Xue 
et al., 2007) 
MPTP mice (Genc 
et al., 2001) 
MPTP-mice (Puskovic et 
al., 2006) 
6-OHDA rat (Xue et al., 
2007) 
Insulin-like growth 
factor (IGF1/2) 
Knusel et al., 1990 6-OHDA rat 
(Quesada and 
Micevych, 2004) 
6-OHDA rat (Ebert et al., 
2008) 
Fibroblast growth 
factor (bFGF/FGF-2) 
Engele and Bohn, 
1991 
6-OHDA rat 
(Shults et al., 
2000) 
MPTP monkey (Fontan et 
al., 2002) 
Vascular endothelial 
growth factor (VEGF) 
Silverman et al., 
1999 
6-OHDA rat 
(Yasuhara et al., 
2004) 
6-OHDA rat (Yasuhara et 
al., 2004; Yasuhara et al., 
2005) 
Platelet-derived growth 
factor (PDGF) 
Nikkhah et al., 
1993 
ND 6-OHDA rat (Mohapel et 
al., 2005) 
 
Transforming growth 
factor ? (TGF-?) 
Alexi and Hefti, 
1993 
ND 6-OHDA rat 
(Fallon et al., 2000) 
Transforming growth 
factor ? (TGF-?) 
Krieglstein and 
Unsicker, 1994 
MPTP mouse 
(Schober et al., 
2007) 
ND 
Bone morphogenetic 
protein (BMP) 
Jordan et al., 1997 6-OHDA rat 
(Harvey et al., 
2005) 
ND 
ND, not described; 6-OHDA, 6-hydroxydopamine; MPTP, 1-methyl-4 phenyl-1,2,5,6-
tetrahydropyridine 
  
The neuropoietic cytokine family (also known as neurokines) include ciliary neurotrophic 
factor (CNTF), interleukin 6 (IL-6) and leukaemia inhibitory factor (LIF), interleukins 11 
(IL-11), cardiotrophin 1 (CT-1), and oncostatin M (OSM) (Sleeman et al., 2000). Of these, 
IL-6,  CNTF  and  CT-1  mostly  affect  nervous  system  development,  and  IL-6  and  CNTF  
show trophic effects on midbrain dopaminergic neurons (Heinrich et al., 2003). CNTF 
was originally considered as a neurotrophin because of its survival-promoting actions on 
parasympathetic neurons from chick ciliary ganglia. Later cloning and sequencing 
revealed that it does not belong to neurotrophins. CNTF has shown trophic and 
differentiating effects on different types of peripheral and central neurons (Sleeman et al., 
2000). CNTF signalling involves its association with CNTFR?, GP130 and LIF-receptor. 
Formation  of  this  complex  leads  to  activation  of  the  Janus  kinase/signal  transducer  and  
activator of transcription (JAK/STAT) signalling pathway. 
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The following sections review previous studies of the GDNF ligands and their receptors, 
and the MANF/CDNF family.  
 
1.2 The GDNF family of neurotrophic factors 
First isolated from glial cell line B49, GDNF showed survival-promoting effects in 
embryonic midbrain culture of dopaminergic neurons by regulating tyrosine hydroxylase 
(TH) expression and dopamine uptake (Lin et al., 1993). GDNF is also a potent survival 
factor of motor neurons (Henderson et al., 1994) and other neuronal subpopulations in the 
central nervous system (CNS) and the peripheral nervous system (PNS). In the CNS, 
GDNF prevented 6-OHDA-induced degeneration of noradrenergic neurons (Arenas et al., 
1995) and, in the PNS, it regulates the differentiation of sympathetic, parasympathetic, 
sensory and enteric neurons (Taraviras et al., 1999; Young et al., 2001; Natarajan et al., 
2002; Gianino et al., 2003). These potent effects in the nervous system mean that GDNF 
can be beneficial for the treatment of Parkinson's disease (see section 1.5.3). Since GDNF 
knockout mice have severe renal agenesis at the time of birth, GDNF signalling is 
essential for kidney morphogenesis (Costantini and Shakya, 2006). In addition, GDNF is 
important for spermatogonia development (Hofmann, 2008). This wide range of 
neuroprotective and therapeutic roles of GDNF makes it an interesting molecule for study.  
Three other homologous proteins, neurturin (NRTN), artemin (ARTN) and persephin 
(PSPN), have been characterized with neurotrophic and neuroprotective actions. NRTN 
has been shown to support survival and proliferation of several neuron populations in the 
central and peripheral nervous system (Kotzbauer et al., 1996; Klein et al., 1997; 
Heuckeroth et al., 1998; Rossi et al., 1999; Golden et al., 2003). Like GDNF, NRTN 
promotes the survival of dopaminergic neurons in vitro and in vivo (Horger et al., 1998). It 
has protective and restorative effects on mesencephalic dopaminergic neurons in animal 
models of Parkinson's disease (Rosenblad et al., 1999). It also regulates the development 
of most of the parasympathetic neurons (Rossi et al., 1999). In addition, NRTN can induce 
branch initiation in kidney development (Davies et al., 1999). 
ARTN is a survival factor for sympathetic and sensory neurons in vitro (Baloh et al., 
1998; Enomoto et al., 2001). In vivo, it protects rodent nigrostriatal dopamine neurons 
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(Rosenblad et al., 2000). It also regulates sensory neurons, and is therefore considered for 
the treatment of chronic pain (Wang et al., 2008). PSPN, the fourth GDNF-like protein, 
promotes the survival of ventral midbrain dopaminergic neurons in culture and in vivo 
after sciatic nerve axotomy and, like GDNF, promotes ureteric bud branching in vitro 
(Milbrandt et al., 1998; Åkerud et al., 2002). PSPN promotes the survival of embryonic 
basal forebrain cholinergic neurons in vitro (Golden et al., 2003). However, PSPN does 
not seem to support any peripheral neurons (Milbrandt et al., 1998; Åkerud et al., 2002). 
PSPN has also been shown to promote both survival and neuritogenesis of midbrain 
dopamine neurons and thus it has been suggested that PSPN, like GDNF and NRTN, 
might have therapeutic potential in the treatment of Parkinson’s disease (Åkerud et al., 
2002). 
These neurotrophic factors together form a family named GDNF family of ligands 
(GFLs).  
Structural features of the GDNF ligands 
GFLs are biologically active covalently linked homodimers, in which each monomer has a 
"cystine knot" topology. The cystine knot is  a covalent ring formed by two cystines and 
the connecting polypeptide chain, through which a third cystine is passed. It confers 
structural stability, and is characteristic of many growth factor families with less than 20% 
sequence identity (Sun and Davies, 1995). Cystine knot growth factors include TGF-?s, 
neurotrophins, platelet-derived growth factor family, and glycoprotein hormones (Sun and 
Davies, 1995). These growth factors are dimeric proteins, and some have an intermonomer 
disulphide bridge in addition to the cystine knot. GFLs are more closely related to TGF-?s 
than  other  cystine  knot  growth  factors.  Like  TGF-?s, GFLs contain seven conserved 
cysteines  in  each  monomer;  six  of  those  form  cystine  knot  (Figure  1.2A),  while  the  
seventh one forms the intermonomer cystine bridge. Neurotrophins and glycoprotein 
hormone families dimerize by noncovalent interactions without the interchain disulphide-
bridge (McDonald et al., 1991; Holland et al., 1994). The overall sequence identity 
between GFLs and the TGF-? superfamily is less than 20%, which makes them a distant 
member of the TGF-? superfamily. 
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Figure 1.2 The GDNF and ARTN structures. A) Structural details of the GDNF monomer (1AGQ; 
chain D). The cartoon is coloured from blue to red. ?1 and ?2 form finger 1, and ?3 and ?4 form 
finger 2. Magenta sticks show the characteristic ‘cystine-knot’. B) Bend angle in the GDNF 
homodimer structures (1AGQ). Top figure shows the bend angle between chain A and B (in red and 
blue),  while  bottom one is  between chain C and D (in the same colours).  The light  green arrows 
mark the hinge angle between the finger domain and the heel. The structure is symmetric about the 
vertical two-fold axis. The lines (black) drawn from the intermonomer S? of Cys101 to E61-C? and 
E61-C?? (black sphere) describes the bend angle (see Methods in Study III). C) The ARTN 
homodimer structure (2GH0, in light blue and magenta) showing the bend angle between the 
monomers.  
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GDNF is expressed as a prepro-protein, from which the signal peptide (pre) is cleaved 
upon secretion. An enzymatic cleavage of the pro-GDNF results in a mature secreted form 
containing 134 residues, which is functional as a disulphide-bonded homodimer. The rat 
GDNF structure (1AGQ; Eigenbrot and Gerber, 1997) is comprised of four ?-strands and 
an ?-helix, called the ‘heel’ (Figure 1.2A). The ?-strands of GDNF form a finger domain 
consisting of two ‘fingers’, finger 1 and finger 2.  
The two monomers form a head-to-tail dimer with the residues on the heel packed against 
the finger domain. In the GDNF crystal, the asymmetric unit contained two independent 
covalent homodimers (chain AB and CD) that differ in the hinge angle between the finger 
domain and the heel in the monomer structure (Figure 1.2B). Superposing the homodimers 
gives a root mean square deviation (RMSD) of 2.6 Å. 
Of the GFLs, ARTN is the only other ligand in the family whose structure has been solved 
(2ASK; Silvian et al., 2006). Its amino acid sequence is more similar to NRTN and PSPN 
than  to  GDNF.  The  ARTN structure  is  similar  to  GDNF (1AGQ) with  the  same cystine  
knot topology. The superposition of GDNF on ARTN gives a RMSD of 2.9 Å for the 
monomer structure but over 4 Å for the homodimer. Silvian and co-workers (2006) 
measured the hinge angle between the heel and the finger domain by calculating the angle 
between the helical axis and a line drawn perpendicular to the disulphide bonds of the 
cystine knot. The hinge angle is 83? in ARTN, and approximately 90? in each of the two 
independent GDNFs. There is intermonomer bend angle in the GFL homodimer, which is 
measured as the angle between the fingertips from the center of the intermonomer cystine 
bridge  (see  Methods,  Study  III).  The  bend angles  for  both  the  dimeric  GDNFs are  146? 
and 168? (Figure 1.2B), and 206? for ARTN2 (Figure 1.2C). Unlike GDNF2, the bend 
angle is same in all the six ARTN2 structures (codes 2ASK, 2GYR, 2GH0, 2GYZ), which 
superimpose  to  an  RMSD value  of  less  than  1Å.  The  bend angle  could  impart  different  
receptor specificities by altering receptor interactions or conformations. 
 
1.3 The GDNF family receptors and signalling 
GFLs require two independent receptor subunits to exert their biological effects: a ligand 
binding GDNF family receptor ? (GFR?), and a common signalling receptor tyrosine 
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kinase RET (Durbec et al., 1996; Trupp et al., 1996). In GDNF signalling, RET delivers 
the intracellular signal but cannot bind ligand on its own. The coreceptor binds the ligand 
but does not signal in the absence of RET. GFL signalling is thus different from other 
members of the TGF-? family, where a heterotetramer complex is formed with the ligand 
binding receptor of a transmembrane serine/threonine kinase (Massague and Weis-Garcia, 
1996).   
1.3.1  Ligand Binding Coreceptor 
GFR?1, first described as GDNFR-? (Jing et al., 1996; Treanor et al., 1996), was 
identified as a GDNF-binding receptor in RET signalling (Durbec et al., 1996; Trupp et 
al., 1996). It is glycosylphosphatidylinositol (GPI)-anchored to the cell surface. Likewise, 
other GFLs also signal through RET by binding a preferred GFR? (Figure 1.3): NRTN 
binds GFR?2 (Baloh et al., 1997; Buj-Bello et al., 1997; Jing et al., 1997; Klein et al., 
1997; Sanicola et al., 1997); ARTN, GFR?3 (Baloh et al., 1998), and PSPN, GFR?4 
(Enokido et al., 1998; Lindahl et al., 2001).  
The ubiquitous in vivo expression  of GFR? compared to RET suggested that the GPI-
anchor of GFR?s could be cleaved to release soluble GFR?s from the cell surface, which 
may subsequently bind to a GFL and activate RET on another cell in trans (Baloh et al., 
1997; Trupp et al., 1997; Yu et al., 1998). It has been demonstrated that endogenous 
soluble GFR?1 is released from cultured gut cells (Worley et al., 2000) and Schwann cells 
(Paratcha et al., 2001). This is analogous to other GPI-anchored receptors, such as the 
CNTF  receptor  ? (CNTFR?),  which  are  also  released  from  cells  and  act  as  soluble  
mediators of the biological activities of their ligands (Davis et al., 1993).  
Each GFR? consists of three homologous cysteine-rich domains (D1, D2 and D3) with a 
C-terminal extension (Figure 1.3). The conserved cysteine pattern and sequence similarity 
(>60%) among D1, D2 and D3 of the coreceptor suggest alikeness in their three 
dimensional structures. The role of D1 is unclear, but it is not necessary for RET binding 
to GFR?1 (Scott and Ibáñez, 2001; Virtanen et al., 2005) and is absent in GFR?4 (Lindahl 
et al., 2001). Leppänen and co-workers (2004) solved the first crystal structure of GFR?1 
D3, revealing a novel fold consisting of five ?-helices connected with five disulphide 
bridges, which was used to build a homology model of GFR?1 D2.   
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Figure 1.3 GFLs,  GFR?s  and  RET.  GFLs  (GDNF,  NRTN,  ARTN  and  PSPN)  bind  a  specific  
coreceptor (GFR?1, GFR?2, GFR?3 and GFR?4), and activate the common signalling receptor 
RET (in light pink). The promiscuity of GFR?1 is shown with dotted arrows. PM, plasma 
membrane; TK, tyrosine kinase domain; GPI, glycosylphosphatidylinositol. Reprinted with 
permission from Acta Cryst. sect. F (Study III) copyrights 2009. 
 
1.3.2  Receptor tyrosine kinase RET 
Receptor tyrosine kinases are transmembrane spanning receptors, which are activated by 
ligand. Receptor tyrosine kinase RET was originally discovered in a gene rearrangement 
and transfection assay using a fibroblast cell line (Takahashi et al., 1985). In 1996, it was 
identified as a signalling receptor for GDNF (Durbec et al., 1996; Trupp et al., 1996). The 
natural  alternative  splicing  of  the  RET  gene  results  in  the  production  of  three  different  
isoforms of the protein. RET51, RET43 and RET9 contain 51, 43 and 9 amino acids in 
their C-terminal tail, respectively. RET51 (1114 residues) and RET9 (1072 residues) are 
the predominant isoforms in which RET occurs. Each isoform of RET is composed of an 
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extracellular region, followed by a single pass transmembrane segment and a cytoplasmic 
tyrosine kinase (TK) domain.  
The extracellular region in RET is significantly different from other receptor tyrosine 
kinases (Anders et al., 2001). It contains four cadherin like domains (CLD1-4) and a 
cysteine rich domain (CRD) (Figure 1.3). The Ca2+ binding site between CLD2 and CLD3 
is essential for folding, secretion, as well as signal transduction (Nozaki et al., 1998; 
Anders et al., 2001).  Although no structure is yet available for any of the extracellular 
domains of RET, each of the CLDs of RET was modeled using the crystal structures of the 
epithelial and the neural cadherins (Anders et al., 2001). On the other hand, the structure 
of the intracellular RET-TK has been solved (see section 1.3.4). 
1.3.3  GFL-GFR?-RET interaction 
The details of the activation mechanisms behind GFL2-GFR?2-RET2 signalling are poorly 
understood. In the original model, it was suggested that dimeric GDNF first binds GFR?1, 
and forms the GDNF2-GFR?12 complex (Jing et al., 1996). It then binds two molecules of 
RET, forming the GDNF2-GFR?12-RET2 complex. Formation of the complex leads to the 
transphosphorylation of the tyrosine kinase domains of RET. In cell-based studies, Schlee 
and co-workers (2006) proposed a new model in which ARTN first binds to a monomer of 
GFR?3, followed by sequential recruitment of one RET molecule and then additional 
molecules  of  GFR?3 and  RET.  The  crystal  structure  of  the  ARTN2-GFR?32 complex is 
symmetric (Wang et al., 2006), which suggests that the heterohexamer complex with RET 
is symmetric too,  but it  does not provide any information on the details  of the activation 
mechanism.   
The ligand coreceptor binding was studied by a number of groups. GFR?1 was originally 
described as a high affinity (?2 pM) coreceptor for GDNF in the absence of RET in 
kidney cell line (Jing et al., 1996; Treanor et al., 1996). Later, radioligand cell-based 
binding assay showed a high affinity binding of 11 pM (Kd) between GDNF and GFR?1 
only in the presence of RET (Cik et al., 2000). The authors observed low levels of RET 
mRNA in HEK293 cells, and suggested that this low level expression of RET might have 
influenced the affinity of GDNF in previous studies by Jing et al. (1996).  
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In cell-based binding assays, the GDNF finger loop residues E61, L114 and Y120 were 
identified as critical for GFR?1 binding (Eketjäll et al., 1999), but only mutation E61A led 
to more than ten-fold reduction in RET activation. The mutations L114A and Y120A, with 
insignificant GFR?1 binding affinity, still phosphorylate RET in a GFR?1 dependent 
manner. The authors suggested that these mutations interact with a binding site formed by 
a pre-associated GFR?1-RET complex. The mutations L118A and I122A also showed a 
more than five-fold reduction in coreceptor binding. These observations gave the first 
evidence that the coreceptor-binding site was in the GDNF finger domain.  
On the GFR? side, Scott and Ibáñez (2001) constructed chimeric GFR?s, mapped GDNF 
binding to the central region of GFR?1 (D23145-348), and identified two triplets, 224RRR226 
and 211MLF213,  that  are  critical  for  the  ligand  binding.  Based  on  a  homology  model  of  
GFR?1 D23, a number of residues (F213, R217, I219, R224, R225, R226, R240, 
Y254/I255, R257/R259, D262/E280 and E323/D324) surrounding these triplets were 
mutated, and binding affinity was measured using radioligand cell-based binding and 
scintillation proximity assays (Leppänen et al., 2004). Four critical residues (F213, R224, 
R225 and I229) significantly affected the GDNF binding affinity. Nonetheless, these 
mutations still mediated GDNF-dependent RET phosphorylation, which suggests that 
GDNF-GFR?1 interactions can largely be compromised without losing GDNF-induced 
RET activation (Leppänen et al., 2004).  
The crystal structure of the ARTN2-GFR?32 complex contained domain 2 and 3 (D23) of 
GFR?3, where D3 stabilizes D2 (Wang et al., 2006). The structure showed that the ARTN 
fingers insert  into the center of the triangular ?-spiral  of GFR?3 D2, and a salt  bridge is 
formed at the binding interface between E61ARTN, R171GFR?3 and R224GFR?3  (GDNF and 
GFR?1 numbering). 
Like GDNF, NRTN and ARTN can also signal through RET-GFR?1 (Creedon et al., 
1997; Cik et al., 2000; Carmillo et al.,  2005).  On  the  other  hand,  GDNF  can  also  
phosphorylate RET via GFR?2, though it is less effective than NRTN (Jing et al., 1997). 
These in vitro results  suggest  the  existence  of  cross  talk  among  GFL-GFR? pairs,  with  
GFR?1 being the most promiscuous coreceptor for GDNF, NRTN and ARTN (Figure 1.3) 
(Airaksinen et al., 1999). However, PSPN cannot signal through GFR?1-RET even in 
 25 
vitro (Enokido et al., 1998). The biological relevance of cross talk signalling is poorly 
understood, and the structural basis of specificity among GFLs is unclear. 
In the absence of ligand, GFR?s (GFR?1 and GFR?2) associate with RET in 
coimmunoprecipitation experiments (Treanor et al., 1996; Klein et al., 1997). However, 
the GFR?-RET interaction is weak (Sanicola et al., 1997), and ligand stabilizes the 
association between GFR?1 and RET (Treanor et al., 1996; Klein et al., 1997). Therefore, 
it is thought that RET binds a composite surface formed over the ligand-coreceptor 
complex. Homologue scanning mutagenesis studies of RET extracellular domains 
suggested that the first domain of RET, CLD1, may be involved in interacting with 
GDNF-GFR?1 (Kjær and Ibáñez, 2003a). However, cross-linking and mass spectrometry 
experiments indicated that the CLD4-CRD interacts with the ligand-coreceptor complex 
(Amoresano et al., 2005). Making the assumption that RET binds to the same region in 
different GFR?s, Wang et al. (2006) proposed that the conserved GFR? residues N164, 
R169, K202, L255, R257, R259, E280, Q281, N320, E323, E324, N335 (GFR?1 
numbering) form the RET binding surface. 
1.3.4  RET signalling 
Receptor tyrosine kinases contain a cytoplasmic TK domain. The structure of the TK of 
both receptor tyrosine kinase and non-receptor tyrosine kinase is similar. It has a two-
domain architecture comprised of a smaller N-terminal lobe (?90 residues) connected by a 
linker to a larger C-terminal lobe (?200 residues) (Knowles et al., 2006). Based on the 
crystal structure of the insulin-? receptor, Hubbard et al. (1994) proposed that the 
activation loop (A-loop) in the TK interferes with ATP or substrate binding, thus giving 
rise to cis-autoinhibition. The phosphorylation of tyrosine(s) within this A-loop, conserved 
in most tyrosine kinases, induces a structural change that is required to expose the A-loop, 
which allow substrate and ATP binding. The same is true for most non-receptor tyrosine 
kinases, like Src (see Benati and Baldari, 2008).  
Five tyrosine residues Tyr905, Tyr981, Tyr1015, Tyr1062 and Tyr1096 in the RET-TK have been 
studied for their role in downstream signalling activities. Tyr900 and Tyr905 are  in  the  A-
loop structure, and mass spectrometry analysis identified both tyrosines as 
autophosphorylation sites. Phosphorylated Tyr905 stabilizes the active conformation of the 
 26 
TK domain, which in turn results in autophosphorylation of the other tyrosines mainly 
located in the C-terminus tail region of the molecule critical for kinase activity 
(Kawamoto et al., 2004). However, the crystal structures of the RET-TK showed that the 
A-loop structure in both phosphorylated and non-phosphorylated states have the same 
conformation (Knowles et al., 2006). The phosphorylation of Tyr905 showed only a three 
to four fold increase in its catalytic activity in vitro (Knowles et al., 2006), unlike the 
kinases present in other receptors that show a 10-200-fold change (Cheetham, 2004). 
RET-TK thus has an active A-loop conformation, which rules out the cis-inhibitory 
mechanism utilized by most tyrosine kinases (see above). Based on the crystallographic 
dimers in the TK and juxtamembrane-TK structures, an alternative trans-inhibited model 
of dimeric TK was suggested (Knowles et al., 2006), which required a large 
conformational change to relieve this trans-inhibition. The conformational change is 
driven by its binding to the GFL2-GFR?2 complex.  
Docking of adaptor molecules invokes intracellular signalling cascades that ultimately 
lead to biological responses like cell proliferation, survival, differentiation, and neurite 
outgrowth (Schlessinger, 2003). Phosphorylated Tyr905 binds to Grb7/10 adaptors, Tyr981 
to  Src  and  Tyr1015 to phospholipase C-? (PLC-?) (Pandey et al., 1995; Borrello et al., 
1996; Hayashi et al., 2000; Encinas et al., 2004). Tyr1096 and Tyr1062 lie in the C-terminus 
tail region of RET; therefore signalling via Tyr1096, required binding to Grb2, is seen only 
for the longest isoform of RET, RET51. Phosphorylated Tyr1062 binds to variety of adaptor 
proteins including SHC (Src homologous and collagen-like protein), FRS2 (fibroblast 
growth factor receptor substrate 2), Dok1/4/5, IRS1/2 and Enigma (Pützer and Drosten, 
2004). These adaptor proteins lead to RAS/ERK, phosphatidylinositol-3-kinase 
(PI3K)/AKT, mitogen-activated protein kinase (MAPK), and Jun N-terminal kinase (JNK) 
pathways (Figure 1.4) (Ichihara et al., 2004; Kodama et al., 2005). 
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Figure 1.4 RET-GDNF signalling. In the extracellular region, the GDNF homodimer (orange) 
binds  two  molecules  of  GFR?1  (blue).  RET  (light  pink),  dimerizes  by  binding  to  the  GDNF2-
GFR?12 heterotetramer, and phosphorylates intracellular tyrosines leading to various signalling 
pathways. The pathways activated by Tyr1062 are listed here. PM, plasma membrane. 
 
Signalling via Tyr1062 has been shown to be important for GDNF mediated neuronal 
survival and differentiation (Coulpier et al., 2002). For instance MAPK and PI3K-
signalling pathways contribute to neurite growth and neuronal survival (Besset et al., 
2000; Encinas et al., 2001; Natarajan et al., 2002; Srinivasan et al., 2005). It was shown 
that knock-in mice with mutated Tyr1062 had severe defects in the development of the 
enteric nervous system and the kidney (Jijiwa et al., 2004). The PLC-? signalling pathway 
regulates the intracellular level of Ca2+ ions by increasing the level of inositol (1,4,5) 
triphosphate (IP3), but the cellular effects of this pathway following activation by GFL 
action are poorly understood (Mason, 2000). Finally, GDNF-mediated RET signalling can 
also activate Src-family kinases, eliciting optimal neurite outgrowth and neuronal survival 
(Oatley et al., 2007).  
Since each GFL has a specific GFR? to activate the common signalling receptor RET, it is 
possible that different GFLs activate RET differently. The signalling could differ because 
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of different tyrosine phosphorylation, or differences in the duration of phosphorylation. 
The signalling of GFLs via their specific GFR?s did not show any significant differences 
in the phosphorylation of the four key tyrosines (Y905, Y1015, Y1062 and Y1096) in the 
RET-TK (Coulpier et al., 2002). However, Lee and co-workers (2006b) showed that there 
were differences in the phosphorylation profile in a neuroblastoma cell line that expressed 
GFR?1  when  it  was  stimulated  with  GDNF  and  NRTN.  In  addition,  NRTN  -  but  not  
GDNF - induced neurite outgrowth of the same cells, while GDNF (not NRTN) promoted 
their survival. Therefore, it is likely that GFLs differ in their signalling via RET. 
1.3.5  Alternative signalling modes of GDNF 
The nervous system does not express equal amounts of the two GFL signalling receptors, 
as GFR? receptors are much more widely expressed than RET (Trupp et al., 1997; 
Ylikoski et al., 1998; Kokaia et al., 1999). As mentioned before, one possibility is that 
GPI-anchors of GFR?s can be cleaved off and become solubilized and bind GFLs in 
different  cell  populations  to  activate  RET.  On the  other  hand,  GFL together  with  GFR? 
may signal via other alternative receptors (Sariola and Saarma, 2003). For instance, GDNF 
triggers  Src  family  kinase  activation  and  phosphorylation  of  ERK/MAPK  and  PLC-? in 
RET-deficient cell lines and primary neurons (Poteryaev et al., 1999; Trupp et al., 1999). 
Paratcha and co-workers (2003) demonstrated that neural cell adhesion molecule (NCAM) 
functions  as  an  alternative  signalling  receptor  for  GFLs.  The  three  main  isoforms  of  
NCAM vary only in their cytoplasmic region. These are: GPI-anchored (120 kDa), short- 
(140 kDa) and long-cytoplasmic domain (180 kDa) forms. The extracellular region of 
NCAM consists of five N-terminal immunoglobulin (Ig) domains followed by two 
fibronectin-like domains. NCAM signalling is involved in neurite outgrowth (Hansen et 
al., 2008). Both GFR?1- and NCAM-knockout mice showed similar defects in migration 
of neuronal precursors in the rostral migratory stream, a migratory pathway that delivers 
cells from the subventricular zone to the olfactory bulb during postnatal and adult life, 
while no such phenotype was observed in mice lacking RET (Paratcha et al., 2003). In 
association with GFR?1, NCAM binds GDNF with high affinity (Kd = 1.1 nM), and 
activates Fyn (Src like kinase) and FAK (Focal adhesion kinase) in the cytoplasm 
(Paratcha et al., 2003). Unlike RET, NCAM can interact directly with GDNF, and NCAM 
deletion constructs and site-directed mutagenesis studies identified the third Ig domain of 
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NCAM as necessary for its interaction with GDNF (Sjöstrand et al., 2007). Recent cell-
based cross-linking experiments showed that D1 of GFR?1 interacts with the fourth Ig 
domain of NCAM (Sjöstrand and Ibáñez, 2008). 
GDNF is also shown to signal via another receptor tyrosine kinase MET, the signalling 
receptor for hepatocyte growth factor. GDNF induces MET phosphorylation in RET-
deficient/GFR?1-positive cells, and GFR?1/RET co-expressing cell lines (Popsueva et al., 
2003). In RET-deficient/GFR?1-positive cells, GDNF stimulates branching but not 
chemotactic migration. On the other hand, GFR?1/RET co-expressing cells showed both 
branching and chemotaxis, which mimics the effects of hepatocyte growth factor 
signalling through MET. However, GDNF does not immunoprecipitate MET, which 
indicates no direct involvement of GDNF/GFR?1 and MET.  
In addition to transmembrane receptor mediated signalling, GDNF seems to utilize novel 
signalling modes which lead to synapse development and maturation in ventral midbrain 
dopaminergic neurons and spinal cord motorneurons (Bourque and Trudeau, 2000; Wang 
et al., 2002). Investigation of homophilic interactions between GFR?1s showed that 
GDNF triggers binding between microspheres coated with GFR?1 and cells expressing 
GFR?1 (Ledda et al., 2007). These experiments suggested that there is GDNF dependent - 
but RET independent - trans-homophilic binding between GFR?1 molecules and cell 
adhesion between GFR?1 expressing cells. The localization of GFR?1 to both pre- and 
post-synaptic compartments in hippocampal neurons, and the reduced number of 
presynaptic sites formed during synaptogenesis of GDNF heterozygous mice suggests an 
important role of GDNF and GFR?1 in synaptogenesis (Ledda et al., 2007). On the other 
hand, several cell adhesion molecules, including cadherins, protocadherins, integrins, 
NCAM, L1, SynCam and neurexin-neuroligin, have been found to be involved in 
controlling synaptic development (Yamagata et al., 2003). Other than cell adhesion 
molecules, secreted growth factors, such as BDNF, have also been implicated in synapse 
formation and plasticity (Schinder and Poo, 2000), but the mechanism by which GDNF 
and GFR?1 contribute to this processs is unique, as it combines features of both 
membrane bound and soluble signals (Ledda et al., 2007).  
However, RET-independent GDNF signalling mechanisms are quite unclear. 
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1.3.6  Lipid rafts in GDNF signalling 
Lipid rafts are dynamic assemblies of cholesterol and sphingolipids in the membrane 
bilayer. Src family kinases, GPI-anchored and other signalling proteins in the intracellular 
regions are localized in lipid rafts. It was thus suggested that rafts might be essential 
signalling compartments in the cell membrane (Paratcha and Ibáñez, 2002). GPI-anchored 
GFR?s are also positioned in lipid rafts. Cholesterol depletion with methyl-?-cyclodextrin 
reduces GDNF-dependent activation of MAPK and AKT kinases (Tansey et al., 2000). 
Furthermore, interaction of RET with Src family kinases required its localization in lipid 
rafts. Therefore, it was suggested that RET signalling occurs in lipid rafts (Tansey et al., 
2000; Encinas et al., 2001).  
Paratcha and co-workers (2001) showed that stimulation of RET-expressing cells with 
GDNF and soluble GFR?1 also recruits RET to lipid rafts, and potentiates the survival and 
differentiation of motor neurons. However, the recruitment of RET to lipid raft through 
soluble GFR?1 was delayed compared to that of GPI-GFR?1. During trans signalling, 
therefore RET may first be activated outside rafts and is then recruited into the rafts. In 
this model, the GDNF2-GFR?12-RET2 complex is associated with soluble SHC, and RET 
is then recruited to lipid rafts through a direct or indirect association with FRS2 (Paratcha 
et al., 2001; 2002). Intriguingly, both adaptor molecules (FRS2 and SHC) bind to the 
same phosphotyrosine residue Tyr1062 (Paratcha et al., 2001). 
1.3.7  Heparan sulphate in GDNF signalling 
Heparan sulphate (HS) is localized on the cell surface and the extracellular matrix, and is 
synthesized as a proteoglycan composed of a protein core with multiple 
glycosaminoglycan (GAG) chains. The biosynthesis of HS involves post incorporation 
modifications of hexoses in the nascent polysaccharide chains. Such modifications include 
the epimerization of glucuronate residues to iduronate and their possible subsequent O-
sulphation at the C-2 position (reviewed in Lindahl, 1994), which is catalyzed by a 
specific HS 2-O-sulphotransferase (HS2ST). Heparan sulphate is required for 
development of renal collecting ducts in vivo and in culture (Bullock et al., 1998). Mice 
homozygous for disruption of the HS2ST gene exhibit a variety of developmental defects, 
 31 
but the most striking phenotype is the absence of kidneys, which is very similar to that of 
GDNF, RET and GFR?1 gene knockouts (Bullock et al., 1998). 
GDNF was originally purified using a heparin-sepharose column (Lin et al., 1993). 
Heparin promoted the GDNF-induced upregulation of tyrosine-hydroxylase mRNA 
(Tanaka et al., 2002). It indicated that membrane bound GAGs are involved in GDNF 
signalling. Barnett and co-workers (2002) showed that heparinase III treatment or the 
addition of exogenous heparin inhibits RET phosphorylation in kidney cell line, and 
suggested that heparan sulphate GAGs mediate a direct interaction between GDNF and its 
receptors. Rickard and co-workers (2003) also showed that GDNF binds highly sulphated 
heparan sulphates. Using enzyme-linked immunosorbent assay (ELISA), the interaction 
between GDNF and heparin  was  shown to  be  dependent  on  the  2O-sulphate  moieties  of  
the GAG chains (Davies et al., 2003; Rickard et al., 2003).  
Hileman et al. (1998) studied a number of GAG-protein interactions, and described a 
consensus sequence, which brings basic amino acids into proximity. Using this criterion, 
Barnett and co-workers (2002) suggested that the N-terminus of GDNF and a region of 
residues 188-196 in D2 of GFR?1 are probable binding sites for heparin. Alfano et al. 
(2007) confirmed that the N-terminus of GDNF binds heparin, and showed by deleting the 
N-terminus of the GDNF that heparin neither promotes nor inhibits GFR?1 binding to 
GDNF. Also, the authors suggested that GFR?1 did not bind to heparin column. Other 
GFLs,  except  PSPN,  also  have  a  heparin  binding  sequence:  NRTN  seems  to  have  a  
positively charged arginine rich region in its N-terminus, while ARTN has positively 
charged residues in its N-terminus and the pre-helix region. Mutagenesis showed that the 
latter region binds heparin (Silvian et al., 2006). Both affinity chromatography and ELISA 
showed that heparin affinity increases in the order GDNF<NRTN<ARTN (Alfano et al., 
2007). However, the in vivo role of heparin or heparan sulphate in GDNF signalling is still 
unclear. 
There are two predominant ways in which GAGs might facilitate signalling by growth 
factors. One possible role for GAGs, which are borne by abundant proteoglycans 
associated with the plasma membrane, is to bind quantities of growth factor with relatively 
low affinity and thereby increase the local concentration of growth factor at the plasma 
membrane where its high affinity receptor is situated. Like other growth factors, GFLs can 
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bind to heparan sulphate side chains of extracellular-matrix proteoglycans, which might 
restrict their diffusion and raise their local concentration (Hamilton et al., 2001). Another 
possibility is that heparan sulphates mediate signalling by receptor dimerization, as seen in 
many cytokines. For instance, heparan sulphates dimerize FGF-2 and subsequently 
dimerize and activate the receptor tyrosine kinase (Rapraeger et al., 1991; Yayon et al., 
1991). The interaction of heparan sulphates in GDNF cannot be responsible for GDNF 
dimerization, as it is a covalent homodimer. However, it may stabilize the interaction 
between GDNF and GFR?1, or GDNF-GFR?1 and RET. 
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1.4 MANF and CDNF family of neurotrophic factors 
Like GDNF, two new neurotrophic factors, mesencephalic astrocyte-derived neurotrophic 
factor (MANF, Petrova et al., 2003) and conserved dopamine neurotrophic factor (CDNF, 
Lindholm et al., 2007) also support the survival of midbrain dopaminergic neurons. These 
proteins with eight cysteines form the first family of neurotrophic factors, which are also 
found in invertebrates. The spacing between the cysteines is strictly conserved from 
vertebrates to invertebrates (Figure 1.5). Since MANF/CDNF do not have cystine-knot 
pattern, their sequences are dissimilar to GFLs and neurotrophins. However, these novel 
proteins are secreted growth factors that exist as monomers. In addition to its role as a 
neurotrophic factor, MANF has been shown as an ER soluble protein with a cytoprotective 
role (Mizobuchi et al., 2007; Apostolou et al., 2008). The mechanisms behind the 
neuroprotective and cytoprotective functions of MANF and CDNF have not been 
discovered yet; there is not even a putative receptor for these neurotrophic factors. 
1.4.1  MANF as a neurotrophic factor 
MANF, a novel secreted neurotrophic factor of 18 kDa (158 amino acids), was first 
identified from a rat mesencephalic astrocyte cell-line (Petrova et al., 2003). MANF is 
also  known as  ARMET (arginine-rich  mutated  in  early  stage  of  tumors),  because  it  was  
originally discovered as a human gene highly mutated in a number of cancers (Shridhar et 
al., 1996). The name ARMET is misleading as it refers to an arginine-rich region in the N-
terminus, which is not part of the mature protein. MANF supported the survival of specific 
embryonic midbrain dopaminergic neurons in vitro, but showed no effects on serotonergic 
or GABAergic neurons (Petrova et al., 2003). The presence of MANF mRNA and protein 
in the midbrain of embryonic mouse suggested that MANF might have a role in 
embryonic development of dopaminergic neurons (Lindholm et al., 2008). Further in situ 
hybridization and immunohistochemistry experiments showed that MANF is widely 
expressed in neuronal and non-neuronal tissues in developing and adult mouse (Lindholm 
et al.,  2008).  In  the  brain,  relatively  high  levels  of  MANF were  detected  in  the  cerebral  
cortex, hippocampus and cerebellar Purkinje cells (Lindholm et al., 2008).  
MANF also showed neuroprotection and neurorestoration in a 6-OHDA model of PD 
(Voutilainen et al., 2009). An intrastriatal MANF injection six hours before a striatal 6-
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OHDA injection was able to prevent the degeneration of nigral dopaminergic neurons. In 
neurorestoration experiments, four weeks after the 6-OHDA lesions, MANF induced 
functional recovery of the mesencephalic dopaminergic system (Voutilainen et al., 2009). 
MANF administration into the cerebral cortex of adult rats before middle cerebral artery 
occlusion significantly reduced the volume of infarction as measured after two days, and 
reduced apoptosis in ischemic cortex (Airavaara et al., 2009). MANF pre-treatment also 
improved motor recovery after stroke, although with some delay (Airavaara et al., 2009). 
Adding recombinant MANF to the culture medium of cardiac myocytes prevented cell 
death induced by stimulated ischemia (Tadimalla et al., 2008).  
Despite the existence of neurotrophic principles and interactions in the Drosophila 
nervous system, no neurotrophic factors so far have been described (Jaaro et al., 2001). 
However, Drosophila melanogaster (Dm)  and  Caenorhabditis elegans (C. elegans) also 
express a protein, which is more than 45% identical to human MANF. Based on high 
homology between vertebrate MANF/CDNF and invertebrate MANF sequences, it was 
predicted that invertebrate MANF is also a neurotrophic factor (Lindholm et al., 2007). 
Recently, human MANF rescued a Dm-MANF gene knockout lethality, which suggested 
that Dm-MANF is a functional ortholog of mammalian MANF (Palgi et al., 2009).  
1.4.2  CDNF as a neurotrophic factor 
CDNF is a vertebrate specific paralog of MANF. It is also known as ARMET-like 1 
protein. It has been characterized as a trophic factor for dopaminergic neurons in vivo 
(Lindholm et al., 2007), and it protects and repairs these neurons in vivo in a rat 6-OHDA 
model of PD (Lindholm et al., 2007). Injecting CDNF, before 6-OHDA, into the striatum 
significantly reduced amphetamine-induced ipsilateral turning behaviour and almost 
completely rescued dopaminergic TH-positive cells in the substantia nigra.  In the 
neurorestorative experiments, CDNF was injected into the striatum four weeks after the 
lesion. After eight weeks of the CDNF injection, significant recovery of motor function 
was noticed. These protective and restorative effects were comparable to those induced by 
GDNF (Lindholm et al., 2007). Like MANF (Lindholm et al., 2008), CDNF is also 
expressed in different human and mouse tissues, including the brain (Lindholm et al., 
2007). In line with the observed neurotrophic activities, MANF and CDNF have been 
shown to be secreted proteins (Lindholm et al., 2007; 2008).  
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Figure 1.5 Multiple sequence alignment of MANF and CDNF homologues. 17 MANF and 11 
CDNF sequences were selected for alignment. Separate multiple alignments from MANF and 
CDNF sequences, omitting the signal sequence, were produced using the CLC sequence viewer. 
The first five residues from the mature CDNF sequences and the last 19 residues in MANF-C (17 in 
CDNF-C)  are  not  shown  in  the  alignment.  All  cysteines  and  the  two  CXXC  motifs  (boxed)  are  
conserved in both MANF and CDNF. The residues are coloured on the basis of conservation: 
conserved residues (>80% identity) in blue, semi-conserved (60-80% identity) in black and other 
(<60% identity) in red. The consensus is shown in the bottom row with conserved residues (>80% 
identity)  in  uppercase and all  others  as  ‘-’.  X.  tropicalis, Xenopus tropicalis; X. leaevis, Xenopus 
leaevis; C. elegans, Caenorhabditis elegans; F. worm, Filarial worm; Dm, Drosophila 
melanogaster; D. pseudo, Drosophila pseudoobscura; A. gambiae, Anopheles gambiae; A. aegypti, 
Aedes aegypti. Modified and reprinted with permission from PEDS (Study II) copyrights 2009.  
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In addition, several non-neuronal tissues of embryonic and adult rats show similar 
expression of MANF and CDNF (Lindholm et al., 2007; 2008). In the tissue samples 
analyzed, high levels of MANF mRNA and protein were detected in the liver and testis, 
whereas CDNF mRNA and protein levels were relatively high in skeletal muscle, heart 
and testis (Lindholm et al., 2007; 2008). 
1.4.3  MANF and CDNF in the ER  
In addition to neurotrophic functions as a secreted protein, MANF is localized in the ER, 
and is upregulated by ER stress (Mizobuchi et al., 2007; Apostolou et al., 2008). It was 
first shown to be upregulated by tunicamycin treatment (Lee et al., 2003). Other reagents 
that cause ER stress, such as expressing incorrectly folded insulin, showed MANF 
upregulation in the pancreatic ? cells (Mizobuchi et al., 2007). Apostolou and co-workers 
(2008) have shown that MANF plays an important role in protecting cells against 
tunicamycin and thapsigargin-induced cell death. In rat, MANF was upregulated by 
cerebral ischemia, which is again an ER stress inducer (Apostolou et al., 2008). In 
addition, myocardial infarction in mouse heart leads to overexpression of MANF 
(Tadimalla et al., 2008). Thus, MANF can function as an ER stress responsive gene in the 
heart and the brain. KDEL-like sequences at the C-terminus also indicate that MANF and 
CDNF are expressed into the ER lumen (Mizobuchi et al., 2007). However, using 
Brefeldin A assay, which inhibited the trafficking from the ER to the Golgi, Apostolou et 
al. (2008) showed that MANF and CDNF secrete via classical ER-golgi pathway 
(Apostolou et al., 2008). Therefore, MANF is ER-resident protein, which is secreted also. 
It was proposed that MANF and CDNF might facilitate the removal of misfolded proteins 
from the ER by degradation and/or enhancing protein folding or controlling the activation 
of ER stress sensors (Apostolou et al., 2008). However, CDNF expression was not 
regulated in upon ER stress, so it must have a constitutive role in the ER (Apostolou et al., 
2008). 
In normal physiology, ER stress is ultimately caused by the accumulation of misfolded 
proteins in the ER, which initiates unfolded protein response (UPR) (Marciniak and Ron, 
2006). By UPR, the protein folding capacity and degradation of misfolded proteins is 
increased  inside  the  cell,  and  molecular  chaperones  function  to  refold  proteins,  and  ER  
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associated protein degradation removes misfolded proteins. As MANF and presumably 
CDNF are involved in cytoprotection in the ER, they might function in protein folding. 
1.4.4  Saposins and SAPLIPs 
The MANF and CDNF structures solved in this study have a similar fold to saposins (see 
section 4.2.1.1). Saposins (sphingolipid activator proteins) A, B, C and D are derived from 
a single precursor, prosaposin, from which they are proteolytically cleaved (Kishimoto et 
al., 1992). These small heat-stable glycoproteins (12-14 kDa) have identical pattern of six 
cysteines residues. Saposins are required for the lysosomal hydrolysis of a variety of 
sphingolipids (reviewed in Vaccaro et al., 1999). Each of the four saposins promotes the 
degradation of particular sphingolipids. Functional deficiencies of saposins lead to 
sphingolipid storage diseases, which are characterized by accumulation of lipid aggregates 
within the lysosomes. Prosaposin knockout mice die shortly after birth due to 
accumulation of glycosphingolipids in cells and neurodegeneration (Fujita et al., 1996). 
The neurodegeneration in prosaposin knockout studies indicated that prosaposin is a 
trophic factor for neurons. Consistent with this, prosaposin promoted the survival of 
cultured hippocampal neurons and the regeneration of sciatic nerve (Kotani et al., 1996). 
Also,  prosaposin  and  saposin  C  promote  neurite  outgrowth  (O'Brien  et al., 1994). A 
peptide sequence of about 18 residues from the N-terminus of saposin C was shown to 
rescue dopaminergic neurons in a mouse MPTP-model of PD (Liu et al., 2001). However, 
the signalling mechanism of prosaposin and saposins is unclear. Recent in vitro 
experiments showed that prosaposin signalling occurs through lipid rafts (Sorice et al., 
2008).  
The structure of saposins consists of four to five ?-helices connected by three disulphide 
bridges (Figure 1.6A). Saposins exist in two conformations: ‘closed’ and ‘open’ (Ahn et 
al., 2003; 2006; Hawkins et al., 2005). In the closed state, the helices are packed to form a 
‘folded-leaf’ structure so that a hydrophobic core is formed. In the open state, this 
hydrophobic core is exposed out. This conformational change in saposins is dependent on 
pH  and  presence  of  lipids  (see  below).  For  instance,  saposin  B  was  crystallised  as  a  
homodimer with the hydrophobic core opened out to bind lipids (Ahn et al., 2003) (Figure 
1.6B). 
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A number of proteins have been found with saposin-like fold in a globular conformation. 
These saposin-like proteins (SAPLIPs) (SCOP; Murzin et al., 1995) include surfactant 
protein B (SP-B) (Johansson et al., 1991), NK-lysin (Liepinsh et al., 1997), granulysin 
(Anderson et al., 2003), amoebapores (Zhai and Saier, 2000; Hecht et al., 2004), 
prophytepsin (Kervinen et al., 1999) and domains of acid sphingomyelinase (Schuchman 
et al., 1991) and acid acyloxyacyl hydrolase (Hagen et al., 1991). Like saposins, SP-B is 
generated from a larger precursor that contains, in addition to SP-B, two other similar 
domains (Zaltash and Johansson, 1998). SP-B lowers surface tension at the liquid-gas 
interface in the lung. NK-lysin and granulysin are produced by natural killer cells and 
cytotoxic T-lymphocytes, and function as antimicrobial proteins. Amoebapores form ion 
channels in the membrane of a target cell by oligomerisation, which leads to cell death 
(Zhai and Saier, 2000; Hecht et al., 2004).  
 
Figure 1.6 Saposins A and B in monomeric and dimeric conformations, respectively. (A) Saposin 
A structure (PDB 2DOB) showing ‘folded-leaf’ saposin fold in closed conformation coloured as 
rainbow. Disulphide bridges are in dark pink. (B) Saposin B (PDB 1N69) as homodimer. One 
monomer is in cartoon (yellow), and the other one is shown in electrostatic surface representation. 
Bound phspholipid is shown as cyan sticks. Colour scheme in surface representation: blue, 
positive; red, negative and white, hydrophobic residues. 
Saposins and SAPLIPs have a wide range of functions, but all seem to interact with 
membranes or lipids (Bruhn, 2005). Saposins A-D are lysosomal proteins that bind 
galactosyl- and glucosyl-ceramides (Vaccaro et al., 1999). Saposins are acidic proteins 
with isoelectric points around four to five, and the dimeric saposin B structure suggests 
that conformational changes in the saposin structure may facilitate the extraction of target 
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lipids from the membrane (Ahn et al., 2003). SP-B and amoebapore peptides also bind to 
negatively charged headgroup of lipids (Vaccaro et al., 1999). Lipid binding by the 
SAPLIP domain is required for vacuolar targeting of prophytepsin, a plant aspartic 
protease (Kervinen et al., 1999). NK-lysin and granulysin are basic proteins, and the 
positively charged lysines and arginines on their surface may be required for membrane 
binding and lysis (Miteva et al., 1999; Sánchez-Barrena et al., 2003). Molecular dynamics 
simulations and site-directed mutagenesis experiments suggested that the lysine residues 
in helices ?1 and ?5 at saposin C provide a base for membrane anchoring by interacting 
with the anionic phospholipids (Liu et al., 2005).  
 
1.5 Diseases related to GDNF-RET signalling and MANF/CDNF   
 
1.5.1  Knockout studies in GDNF-GFR?1-RET system 
Mice lacking RET, GDNF, or GFR?1 all die soon after birth and share similar phenotype 
of kidney agenesis and absence of enteric neurons (Schuchardt et al., 1994; Moore et al., 
1996; Pichel et al., 1996; Sánchez et al., 1996; Cacalano et al., 1998; Enomoto et al., 
1998). In RET-/- and GFR?1-/- homozygotes, the animals show renal abnormalities 
(Schuchardt et al., 1994; Enomoto et al., 1998). However, unlike the GDNF+/- mice, 
where up to 30% of the animals have kidney abnormalities (Sánchez et al., 1996), 
GFR?1+/- and RET+/- mice have normal kidneys compared to the wild type animals 
(Schuchardt et al., 1994; Enomoto et al., 1998). In addition to role in kidney development, 
GDNF induced cell signalling also regulates the spermatogonial self-renewal and 
differentiation in GDNF transgenic mice (Meng et al., 2000; 2001; Kubota et al., 2004). 
On the other hand, the NRTN-/-, GFR?2-/- (Garces et al., 2000), ARTN-/- and GFR?3-/- 
mice (Honma et al., 2002), unlike the GDNF-/-, GFR?1-/- and RET-/- mice, are viable 
and fertile.  
1.5.2  RET mutations 
The proto-oncogene RET has attracted considerable clinical interest because of the range 
of mutations found in diverse conditions that include Hirschsprung’s (HSCR) disease and 
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a variety of cancers involving the thyroid gland. The mutations in its gene are spread 
throughout the coding sequence. Diseases associated with RET mutations can be grouped 
into two classes according to its gain-of-function or loss-of-function. Loss-of-function 
mutations in RET impair its phosphorylation, and causes HSCR disease or aganglionic 
megacolon (Plaza-Menacho et al.,  2006).  Patients  with  HSCR  disease  suffer  from  a  
variable lack of neurons in the distal segments of the enteric nervous system, which leads 
to intestinal obstruction or chronic constipation (Lantieri et al., 2006). These mutations, 
which were scattered all over the RET, are found in up to 50% of the familial and 15% of 
the sporadic cases (Hofstra et al., 2000). Mutations in the RET extracellular region leading 
to unfolded or incorrectly folded RET affects its binding to the ligand-coreceptor complex 
and inhibits downstream pathway (Kjær and Ibáñez, 2003b). Loss-of-function in RET 
could also be caused by mutations in the TK domain which adversely affects its stability 
or activity (Carlomagno et al., 1996; Iwashita et al., 1996). Other mutations of critical 
tyrosines in the RET-TK affect the binding of the adaptor molecules, which inactivates the 
signalling (Geneste et al., 1999).  
On the other hand, gain-of-function mutations of RET that induce constitutive 
dimerization or constitutive kinase activation causes multiple endocrine neoplasia type 2 
(MEN2), an inherited cancer syndrome characterized by medullary thyroid carcinoma 
(MTC) (Kodama et al., 2005). The disease has three clinically distinct subtypes, ranging 
from the later onset, less severe, familial medullary thyroid carcinoma (FMTC), to more 
severe MEN2A, characterized by MTC, pheochromocytoma and parathyroid hyperplasias. 
MEN2B, which is characterized by MTC and pheochromocytoma, as well as by an array 
of developmental abnormalities including marfanoid habitus, mucosal neuromas, and 
myelinated corneal nerves, is the most aggressive form of MEN2.  
Six well-characterized cysteine mutations in CRD (C609, C611, C618, C620, C630 and 
C634) are associated with MEN2 syndromes (Mulligan et al., 1995). The mutations C630 
and C634 are related to the MEN2A and FMTC phenotypes. MEN2A is associated most 
frequently with C634R mutation, which leads to its partial misfolding due to formation of 
abnormal cystine bridges between the two RET molecules. Other mutations (C609, C611, 
C618, C620) are associated not only with the MEN2A and FMTC phenotypes, but also 
with the HSCR disease.  
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The most aggressive oncogenic phenotype, MEN2B, has been linked to M918T. This 
mutation does not cause the dimerization of the protein, but alters the substrate specificity 
of the kinase; therefore, it affects the downstream signalling pathways (Santoro et al., 
1995; Eng and Mulligan, 1997). Different types of mutations underlie the papillary thyroid 
carcinomas (PTC). Patients with PTC mostly harbour a chromosomal rearrangement in 
which the TK domain of RET is fused at its N-terminus to a soluble protein (Nikiforov, 
2002). It spontaneously forms cytoplasmic dimers, which in turn phosphorylate the TK 
domain, as shown by the constitutive phosphorylation of Tyr1015 and Tyr1062 in RET/PTC 
chimeric protein (Salvatore et al., 2000). The constitutive phosphorylation in PTC variants 
of RET differ from the transmembrane MEN2 variants of RET in their subcellular 
localization.  
1.5.3  GDNF in Parkinson’s disease 
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the impairment 
of motor function due to loss of dopaminergic neurons in the nigrostriatal system (Calne, 
1984). As mentioned before, the neurotoxins 6-OHDA (Simon et al., 1974), MPTP 
(Heikkila et al., 1984) and methamphetamine have been used to create PD model in 
monkeys and rats. A neurotrophic factor can be considered beneficial for PD if it prevents 
the degeneration of dopaminergic neurons exposed to toxins and other insults, and/or it 
provides a therapeutic effect of restoring the function of dopamine neurons (i.e. the 
capacity to synthesize and release dopamine).  
Since GDNF prevents embryonic midbrain dopaminergic neurons from degeneration (Lin 
et al., 1993) and protects them against 6-OHDA and methamphetamine (Cass, 1996; 
Shults et al., 1996), it has been considered as a potential therapeutic agent for treatment of 
PD. In rodent and primate models of PD involving selective degeneration of dopamine 
neurons, GDNF has been shown to be neuroprotective, and its delivery into the cerebral 
ventricles or directly into striatum or substantia nigra improves motor functions (Tomac et 
al., 1995; Gash et al., 1996; Bjorklund et al.,  1997).  The  toxic  effects  of  6-OHDA  are  
related to oxidative stress, mitochondrial dysfunction and apoptotic cell death (Schober, 
2004). Therefore, it is possible that the neuroprotective effects of GDNF may result from a 
reduction in oxidative stress induced by 6-OHDA (Smith and Cass, 2007). 
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The positive results obtained using intracerebroventricular administration of GDNF in 
monkeys (Gash et al., 1996; Zhang et al., 1997) prompted clinical trials in patients with 
PD. Gill and co-workers (2003) infused GDNF directly into putamen via implanted 
catheters in five PD patients in an open trial in Bristol, UK. A marked improvement in PD 
patients was observed, which allowed a randomized, double-blind, placebo-controlled trial 
of bilateral GDNF infusion in 34 subjects with moderately advanced PD, sponsored by 
Amgen (Newbury Park, CA) (Lang et al.,  2006).  In  this  study,  GDNF  did  not  seem  to  
have any impact on the symptoms and three patients produced a neutralizing GDNF 
antibody. It was suggested that GDNF might not have reached putamen and substantia 
nigra, the target tissues. Dr. Slevin and co-workers (2005) administered GDNF into the 
putamen and found considerable improvement in patients. Several adverse effects 
including nausea, loss of appetite, hallucinations and depression have been found in some 
studies (Nutt et al., 2003).  
Alternative techniques like GDNF gene therapy with the use of three viral vector systems, 
adenovirus, adeno-associated virus and lentivirus, have been considered, which have been 
found effective against neurodegeneration and have shown restorative effects in monkey 
and rat models of Parkinson’s disease (Choi-Lundberg et al., 1997; Gash et al., 1998; 
Bjorklund et al., 2000; Kordower et al., 2000). NRTN has also been shown to enhance the 
survival of dopaminergic neurons in rodent and monkey models of PD (Horger et al., 
1998; Rosenblad et al., 1999). In addition, gene transfer of NRTN protects nigral 
dopaminergic neurons in rats (Peterson and Nutt, 2008). However, it produced conflicting 
results in clinical trials, as phase II study failed to induce any beneficial effects in PD 
patients (Peterson and Nutt, 2008).  
Although RET (Schuchardt et al., 1994), GDNF (Moore et al., 1996; Pichel et al., 1996; 
Sánchez et al., 1996), or GFR?1 (Cacalano et al., 1998; Enomoto et al., 1998) knock-out 
mice died at birth due to absence of kidney, no significant differences in substantia nigra 
compared to that of wild-type mice was observed. To study the postnatal survival of 
dopaminergic neurons, Granholm and co-workers (2000) transplanted fetal neural tissues 
from GDNF-/-, GDNF+/-, and wild-type mice into the brain of adult wild-type mice and 
showed that survival of ventral mesencephalic dopaminergic neurons is dependent on 
GDNF. Further studies of GDNF-GFR?1-RET signalling in adult mice nervous system 
using selective RET ablations which allow postnatal survival showed that deficiency of 
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RET causes progressive and late loss of dopamine neurons in the substantia nigra pars 
compacta (Kramer et al., 2007). It also led to degeneration of dopamine nerve terminals in 
striatum and reduced levels of evoked dopamine release. Furthermore, the similar 
phenotype to PD of aged mice suggested that RET is important for the maintenance of 
adult nigrostriatal dopamine system. In contrast, Jain and co-workers (2006) showed that 
RET is not required for survival of midbrain dopaminergic neurons in adult mice. In 
addition, GDNF-RET signalling in relation to PD in humans has not been confirmed yet, 
and no association between HSCR and PD has been found (Lücking et al., 2008). 
Therefore, the importance of GDNF-GFR?1-RET signalling in the nervous system is 
unclear. 
1.5.4  MANF/CDNF in Parkinson’s disease 
Since  clinical  trials  of  GDNF and NRTN in  PD patients  have  not  been  fully  successful,  
other neurotrophic factors such as MANF and CDNF have been investigated for their 
neuroprotective and neurorestorative effects in 6-OHDA or MPTP model of PD. After its 
discovery as a survival factor for mesencephalic dopamine neurons in vitro (Petrova et al., 
2003), MANF showed both neuroprotective and neurorestorative effects in 6-OHDA-
lesioned mesencephalic dopaminergic system. Recent neuroprotective and 
neurorestorative studies of CDNF in the rat model of PD showed that CDNF is as potent 
as GDNF (Lindholm et al., 2007). It is intriguing that the structurally unrelated CDNF and 
GDNF protect and restore nigral dopaminergic neurons. Unlike GDNF, the putative 
receptor for CDNF and MANF and their signalling mechanism are unknown.  
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2.  AIMS OF THE STUDY 
 
The aim of my thesis was to obtain structural and functional information on RET-GDNF-
GFR?1  system,  and  to  characterize  two  novel  neurotrophic  factors:  MANF  and  CDNF.  
My specific goals were: 
1) To structurally characterize the GDNF2-GFR?12 complex.  
 a) To express and crystallize the GDNF2-GFR?12 complex. 
 b) To identify other GFR?1 residues involved at the GDNF binding interface.
 c) To explore the role of heparin in GDNF signalling. 
 d) To identify the structural determinants of ligand specificity. 
2) To find a RET binding site within GFR?1.  
 a) To identify residues involved in RET binding. 
3) To structurally characterize the MANF and CDNF proteins. 
 a) To solve the crystal structure of MANF and CDNF. 
 b) To learn the structure-function relationship of MANF and CDNF. 
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3.  METHODS 
 
Methods used in studies I-III 
Detailed description of materials and methods used can be found in the original 
publications I-III, and the methods used in each study are listed in Table 1. 
Table 1 Methods used in the original publications. 
Method  Study 
Molecular biology   
 DNA sequencing I, III 
 PCR I, III 
 Cloning I, III  
 Protein expression I, III 
 Protein purification I, III 
 Site-directed mutagenesis I 
   
Protein characterization   
 Bradford assay I, III 
 Western blot I, III 
 SDS-PAGE I, III 
 Size exclusion chromatography I, III 
 Ion-exchange chromatography I, III 
 Sequence comparison I, II, III 
   
Crystallography   
 Sitting-drop vapour diffusion/crystallization I, II, III 
 Data collection III 
 Data processing I, II, III 
 Molecular replacement I, II, III 
 Se-MAD II 
 Model building I, II, III 
 Refinement I, II, III 
 Structural alignment I, II, III 
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4.  RESULTS AND DISCUSSION 
4.1 Structural and functional studies of the GDNF2-GFR?12 complex 
The results presented in this section are based on Study I and Study III. 
4.1.1  The crystal structure of the GDNF2-GFR?12 complex (Study I) 
The GDNF2-GFR?12 complex was co-expressed in insect cells and purified using Ni-
affinity and size-exclusion chromatography. Domain 1 of GFR?1 was not included, as it is 
not needed for ligand binding (Virtanen et al., 2005). The complex (3mg/ml) was 
crystallized at +4? C in a well solution of 100 mM HEPES, pH 7.5, 10% polyethylene 
glycol 8000, and 8% ethylene glycol. The crystals belong to space group C2 with single 
molecule of GDNF-GFR?1 per asymmetric unit. The structure was solved by molecular 
replacement using human GFR?3 (domain 2 and 3; D23) from ARTN-GFR?3 (code 
2GH0; Wang et al., 2006) and rat GDNF (code 1AGQ; Eigenbrot and Gerber, 1997) as 
search models with Phaser. The flexible N-terminal region (33 residues) of GDNF and the 
GFR?1 C-terminal extension (76 residues) were not visible in the electron density. The 
final model containing GFR?1-?D1150-349 and GDNF34-134 was  refined  to  Rwork 18.1% 
(Rfree 23.7%). In the structure of the complex, each of D2 and D3 of GFR?1 consists of the 
triangular spiral of five ?-helices folded with five cystine bridges (Figure 4.1). The heparin 
mimic, sucrose octasulphate (SOS), was also bound to D2 of GFR?1. 
The biological heterotetrameric complex is formed by the unique crystallographic two-
fold axis (Figure 4.1). Each monomer in the GDNF homodimer binds GFR?1 on its 
fingertips. At the GDNF-GFR?1 binding interface, the finger domain of GDNF binds 
GFR?1 through the centre of the “triangular helix spiral” formed by ?-helices ?1, ?2 and 
?5 in D2 (Study I).  The key interaction at  the interface is  the formation of the ion triple 
R171GFR?1- E61GDNF-R224GFR?1 (Figure 4.2). Of the other residues in the same region, 
N162GFR?1 buttresses the ion triple interaction by positioning E61GDNF and R171GFR?1. It 
does so by forming hydrogen bonds between the amide group of N162GFR?1, the carboxyl 
group of E61GDNF and the guanidine group of R171GFR?1 (Figure 4.2).  
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Figure 4.1 The GDNF2-GFR?12 heterotetrameric complex. GFR?1 (D2, blue, and D3, red) and the 
GDNF homodimer (in light pink and cyan) are shown in cartoon. The complex is symmetric and 
the  two  heterodimers  are  related  by  the  two-fold  vertical  axis.  SOS is  bound  to  GFR?1  D2.  It  is  
shown as sticks with colour coding: sulphur, yellow; oxygen, red; nitrogen, blue; carbon, cyan. 
Disulphide bridges are shown as yellow sticks. The lines (black) drawn from the intermonomer S? 
of Cys101 to the E61-C? and E61-C?? describes the bend angle. Modified and reprinted with 
permission from J. Biol. Chem. (Study I) copyrights 2008.  
   
 
Figure 4.2 The GDNF-GFR???binding interface. Stereo view of the GDNF-GFR?1 binding 
interface (code 2V5E). The triangular helix spiral of GFR?1 is shown in pale green, and the GDNF 
loops are in yellow. The important binding interface residues are shown in sticks. Colour coding: 
carbon, green (GFR?1), yellow (GDNF); nitrogen, blue and oxygen, red. The interface residues 
mutated in Study I are marked with red labels. 
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On the other side of the ion triple, the hydrophobic interactions involve the packing of 
Y120GDNF between L114GDNF, I175GFR?1 and V230GFR?1. At the periphery of the binding 
interface, I122GDNF is packed between I175GFR?1 and T176GFR?1 (Figure 4.2). 
4.1.2  Insights into heparin- and RET-binding (Study I) 
Here GFR?1, the high affinity GDNF receptor polypeptide, was examined for its affinity 
to heparin (Study I). Both wt-GFR?1 and GFR?1-?D1 bind to the heparin column, but wt-
GFR?1 elutes at a higher NaCl concentration (? 1 M) than GFR?1-?D1, which elutes at 
about 0.5 M NaCl. The reduced binding affinity of GFR?1-?D1 to the heparin column 
suggests that D1 of GFR?1 binds heparin (Study I, Figure 3). This is in contrast to 
previous heparin binding experiments where Alfano and co-workers (2007) do not see 
GFR?1 binding to the heparin column. In addition to heparin binding experiments, the 
crystals  of  the  GDNF2-GFR?12 complex were grown in the presence of SOS. The 
structure of the complex showed SOS bound to the GFR?1 residues R190, K194, R197, 
Q198 and K202 in domain 2 which is consistent with the previously predicted heparin-
binding sequence (see section 1.3.7). Taking into account the biological importance of 2O-
sulphation, I docked a heparin pentasaccharide into the SOS-binding region by keeping 
the 2O-sulphates in a similar orientation to that of SOS. Thus affinity chromatography 
shows that GFR?1 binds heparin, and the modelling and SOS binding in the crystal 
structure provide a region of residues involved in heparin binding (Study I, Figure 3).  
As GDNF is also shown to bind heparin, and Alfano et al. (2007) showed that a 40-residue 
stretch at the N-terminus of GDNF is involved in heparin binding. Deleting this region 
does not affect the interaction between GDNF and GFR?1, and so the heparin-binding site 
in GDNF is distinct from the GFR?1 binding site (Alfano et al., 2007). The N-terminus of 
GDNF was disordered in the previous crystal structure (Eigenbrot and Gerber, 1997). Here 
also only a partial N-terminus (residues 34-40) of GDNF in the structure of the complex is 
ordered (Study I). Intriguingly, residues Q34, R35, K37, R39 in this N-terminus region 
interact with SOS, and therefore SOS mediates interaction between GDNF and GFR?1. 
One  side  binds  D2  of  GFR?1  while  the  other  side  interacts  with  the  N-terminus  of  a  
symmetry-related GDNF (Study I, Figure 3). It thus forms a SOS-linked arrangement of 
the GDNF2-GFR?12 complexes in the crystal. A similar interaction is possible in my 
second crystal structure of the GDNF2-GFR?12 complex,  where  two  NAG  residues  
 49 
attached to N49GDNF bind to the SOS-binding region in GFR?1 (Study III). The two 
complex structures of GDNF2-GFR?12 thus indicate that polysaccharide can mediate 
interaction between the heterotetrameric GDNF2-GFR?12 complexes. They thus may 
explain how the GDNF2-GFR?12 complex is involved in synapse formation (Ledda et al., 
2007); long chains of heparan sulphates attached to the cell surface may link two GDNF2-
GFR?12 complexes on different cells, thereby inducing synaptic interactions between the 
cells (Figure 4.3). 
 
Figure 4.3 Schematic diagram of how heparin might create GDNF2-GFR?12 “dimer of tetramers” 
between cells. The GDNF homodimer is orange and GFR?1 is coloured blue. Heparan sulphate 
chain (cyan) on the cell surface connects GDNF from one GDNF2-GFR?12 complex to GFR?1 on 
a different cell, which might lead to trans signalling. 
 
To  identify  the  RET  binding  site  within  GFR?1,  a  number  of  surface  residues  were  
mutated in GFR?1 D2 and D3 including the SOS-binding residues (Study I): D164, R190, 
K194, R197, Q198, K202, R217, R240, R257 and R259. In addition, I purified the 
previously mutated E323 and D324 (Leppänen et al., 2004). These soluble mutants were 
tested for their ability to phosphorylate RET in ELISA using RET-expressing cells. 
Interestingly, R190A/R197A, K194A, Q198A/K202 and R257A/R259A showed 
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significant reduction in RET phosphorylation and these mutations lie on the SOS-binding 
surface (Figure 4.4).  
 
Figure 4.4 RET phosphorylation assay and the RET binding surface. A) Relative activation in 
ELlSA assays (wt = 100%). MG87-RET  cells  were  used  and  1?g/ml of soluble wt- or mutant 
GFR?1 was added in the presence or absence of 0.1?g/ml of soluble GDNF. Percentage 
stimulation values were obtained by subtracting the individual respective control values, and then 
the percentage stimulation with respect to wt-GFR?1 was calculated. B) Electrostatic surface view 
of GFR?1 D23 showing the proposed RET binding surface. Probable RET-interacting residues are 
marked. Arrows point to the RET and GDNF binding interfaces. Reprinted with permission from 
J. Biol. Chem. (Study I) copyrights 2008. 
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The E323A/D324A double mutant also affects the RET phosphorylation. As none of these 
mutants are on the GDNF binding site, these GFR?1 residues appear to be involved in 
RET binding. Furthermore, RET and heparin binds to the same region in GFR?1 (Figure 
4.4B). It may explain how exogenous heparin inhibited RET signalling (Barnett et al., 
2002); heparin could bind to the R190-K202 region in GFR?1, thereby inhibiting the RET 
binding. 
4.1.3  Comparison between GDNF2-GFR?12 and ARTN2-GFR?32  
Of the four GFL2-GFR?2 complexes, the crystal structures of GDNF2-GFR?12 (Study I & 
III) and ARTN2-GFR?32 (Wang et al., 2006) have been determined. The structures of 
GDNF-GFR?1 (codes 2V5E) and ARTN-GFR?3 (code 2GH0) contained only the two 
binding domains in GFR?. GFR?1 and GFR?3 are highly similar with a root mean square 
deviation of 0.89 Å for 166 C? atoms. From both the crystal structures and previous 
mutagenesis (Eketjäll et al., 1999; Scott and Ibáñez, 2001; Leppänen et al., 2004), it is 
clear that the GFL fingertips bind D2 of the coreceptor. The binding interface in both the 
complexes form an ion triple R224coreceptor-E61ligand-R171coreceptor that is conserved in other 
GFL-GFR? pairs too (Figure 4.5). Mutations R224AGFR?1 and E61AGDNF showed a 
significant loss in GDNF-GFR?1 binding (Eketjäll et al., 1999; Leppänen et al., 2004), 
which suggests that loss of the ion triple interaction significantly affects the binding, and 
R171GFR?1 may be as important as R224GFR?1 and E61GDNF. The ion triple thus appears to 
be the key interaction required for all the ligand-coreceptor complexes. What is the basis 
of GFL-GFR? specificity? 
4.1.3.1  Structural basis of ligand specificity 
Besides the conserved ion triple, the ligand-coreceptor binding interface in different GFL-
coreceptor complexes contained non-conserved residues that contribute differently at the 
interface (Figure 4.5). The ARTN-GFR?3 binding interface involves the packing of 
W120ARTN in a hydrophobic cavity composed of G175GFR?3, M114ARTN and A230GFR?3 
(Figure 4.5B). The equivalent Y120GFR?1 binds to a slightly smaller but deeper pocket at 
the GDNF-GFR?1 interface (see section 4.1.1). Since mutations of Y120 and L114 to Ala 
affect coreceptor binding (Eketjäll et al., 1999), the packing of Y120 is important. It 
appears that the contact residues I175GFR?1 and V230GFR?1 are also important. To find 
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specificity determinants, I mutated I175GFR?1 to glycine, so that it forms a GFR?3-like 
pocket. This resulted in a more than 20-fold reduction in RET phosphorylation (Study I, 
Table 3). This can be explained because the Ile175?Gly mutation increases the size of the 
hydrophobic cavity around Y120GDNF, thereby influencing the complementary binding 
interface.  
 
Figure 4.5 The GFL-GFR??binding interface and the sequence alignment. A) GFR?1 in a surface 
representation (pale green) is positioned under GDNF in yellow loop. B) GFR?3 (in light blue) is 
shown similarly under ARTN in dark red loop. The key differences between GFR?1 and GFR?3 
are shown in orange and the two arginines of the ion-triple are blue. The key GDNF and ARTN 
residues are shown as sticks: carbon, yellow, oxygen, red and nitrogen, blue. C) Alignments of 
segments from the binding interface region of the rat GFR? and GFL sequences along with human 
GFR?1 and human GDNF, respectively. The interface residues within GFR?? shown in Figure A 
have a green background, and those GDNF, a yellow background. Other interface residues are 
marked with asterisks. 
 
On the other hand, the buttressing interaction contributed by N162 to the ion triple in 
GFR?1 (see section 4.1.1) is not present in the ARTN-GFR?3 interface, because 
T170GFR?3 (analogous  to  N162)  is  too  far  to  interact  with  the  ion  triple  (Figure  4.5A  &  
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4.5B). The N162GFR?1 to Ala mutation showed a significant loss of RET phosphorylation 
(Figure 4.4A). This variation of residues (L114GDNF?MARTN, Y120GDNF?WARTN, 
N162GFR?1?TGFR?3, I175GFR?1?GGFR?3 and V230GFR?1?AGFR?3) at the interface affects 
the approach of the ligand fingers: in comparison to GDNF, the finger loops of ARTN 
twist (?20?) about their longitudinal axis and turn (?20?) around a vertical axis in relation 
to the triangular helix spiral of GFR? (Study I, Figure 4).   
Thus the non-conserved core residues at position 114 and 120 in the ligand, and 162, 175 
and 230 in the coreceptor form complementary surfaces at the binding interface (Figure 
4.5C). The variation of these residues forms the basis of specificity among different GFL-
GFR? complexes. In addition, it explains the promiscuity, as the ion triple is conserved 
and forms the primary interaction between GFL and GFR?. The binding is weaker in the 
cross-talk complexes (GDNF binding GFR?3 and vice versa), because mismatch in the 
complementary residues at the interface leads to a weaker ion triple. This is why the 
binding affinity of the cross-talk complexes is much lower than that of the specific 
complexes (Cik et al., 2000; Carmillo et al., 2005). 
As discussed before (see section 1.3.3), GFR?1 does not show any cross talk signalling 
with PSPN. Baloh and co-workers (2000) by making chimeric GFLs, identified three 
critical regions in GDNF, NRTN and ARTN, which are essential to activate GFR?1-RET 
receptor complex: regions I (residues 73-80), II (residues 103-110), and III (residues 120-
127) (Figure 4.6A). Regions I and II do not belong to the coreceptor-binding site, as they 
are not in the fingertips and so these must have a more direct effect on RET activation. 
Regions I and II from GDNF, NRTN and ARTN may either be involved in binding RET, 
or may affect  the homodimeric structural  conformation of the GFLs. As regions I  and II  
are less conserved in GFLs, they probably do not interact with RET. Thus, these regions 
are more likely to influence the structure of the homodimer. I found only two residues D80 
(region I) and R103 (region II), which are conserved in GDNF, NRTN and ARTN - but 
not  in  PSPN  (Figure  4.6).  The  structures  of  GDNF2 and ARTN2 showed that these two 
residues form a unique inter-monomer ion pair (Figure 4.6). This interaction seems to 
prevent  the  movement  of  the  heel,  as  one  side  of  the  heel  is  buried  but  the  other  side  is  
exposed to solvent and forms the D80-R103 ion pair.  
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Figure 4.6 Interaction of the ligand heel with the finger domain, and sequence alignment between 
GFLs. A) Sequence alignment between GFLs (human and mouse sequences) around the buried 
region. The secondary structure is shown at the top and the numbering according to human 
GDNF. D80 and R103 forming ion pair (see Figure B and C) in the GDNF and ARTN structures 
are in light green background. Important differing residues discussed in text are in red. B) GDNF 
homodimer interface. One monomer is in surface representation (in pale green), while other 
monomer, showing heel only, is in cartoon loop in green. The important interface residues, not 
conserved among GFLs, are shown in sticks and brown surface. The inter-monomer ion pair 
between D80 and R103 is also shown. C) The ARTN homodimer as in Figure B. The finger 
domain is in pale yellow surface and heel is in yellow loop. Residue numbering is according to 
the GDNF sequence. Modified and reprinted with permission from Acta Cryst. sect. F (Study III) 
copyrights 2009. 
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Since  regions  I  and  II  from  GDNF/NRTN/ARTN  are  required  to  allow  mouse  PSPN  
chimeras to signal through GFR?1, the intermonomer ion pair between D80 and R103 
may be essential for signalling through the GFR?1-RET receptor complex (Study III). 
This ion pair interaction appears to be required for the structural integrity of GDNF2, 
NRTN2 and ARTN2 - but not PSPN2. The lack of this ion pair in PSPN2 may influence its 
signalling through RET-GFR?4  complex,  which  explains  inability  of  PSPN  to  signal  
through RET-GFR?1 (Enokido et al., 1998). 
4.1.3.2 Structural difference between GFLs indicates novel ways of signalling 
The  monomer  structures  of  GDNF  and  ARTN  differ  with  respect  to  the  hinge  angle  
between the finger and the heel (see section 1.2). This difference in the monomer 
structures is imparted to the GDNF and ARTN homodimers, which thus have different 
bend angles. As can be seen (Figure 4.7), the bend angle difference of 46? in the GDNF- 
and ARTN-coreceptor complexes provide significant dissimilarity in their quarternary 
structures (Figure 4.7C), which is preserved in another crystal structure of the GDNF2-
GFR?12 complex (see section 4.1.4).  
The bend angle of the GFLs may cause differential signalling through RET, since the 
MAPK-luciferase assay showed a faster activation via GDNF than ARTN (Study I, Figure 
4). This may also explain different effects exerted by GDNF and NRTN on GFR?1 
expressing cells as shown by Lee et al. (2006b): GDNF promoted cell survival, while 
NRTN induced neurite outgrowth. The different bend angles could change the 
presentation of the RET tyrosine kinase domains on the inside of the cell. These changes 
in the intracellular region of RET could lead to its interaction with different targets, and 
affect downstream signalling. 
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Figure 4.7  GFL bend angle and comparison of GDNF2-GFR?12 and ARTN2-GFR?32 structures. 
A) Bend angle for the GDNF complex structure (2V5E). Using Pymol (DeLano, 2002), the bend 
angle is measured between the two finger domains of the monomers (in black spheres) from the 
intermonomer disulphide bridge (Figure 1.2). The monomers in the GDNF homodimer are cyan 
and green, and the GFR?1s are blue. B) The bend angle for the ARTN complex structure. ARTN 
homodimer is in magenta and yellow, and GFR?3s in salmon. C) Heterotetramer superposition of 
ARTN2-GFR?32 (code 2GH0) and GDNF2- GFR?12 (code 2V5E) structures. The GFR?3 
structure on the left side in the ARTN-GFR?3 complex (2GH0) was superimposed on GFR?1 in 
2V5E. The GDNF homodimer is  in  cyan and ARTN in magenta.  GFR?1 and GFR?3s are as  in  
Figure  A  &  B.  Modified  and  reprinted  with  permission  from  Acta Cryst. sect. F (Study III) 
copyrights 2009. 
 
4.1.4 Analysis of GFL structural variation (Study III) 
To analyze whether the differences between GDNF and ARTN are due to crystallographic 
artefacts, I crystallized another GDNF2-GFR?12 complex. There were three differences in 
purification and crystallization: first, the new GDNF-complex was purified and 
crystallized in the absence of SOS. Second, I did not treat the purified complex with 
peptide:N-glycosidase F, so that the complex remains glycosylated. Third, the crystals 
were grown at room temperature. The crystals were obtained in a well solution containing 
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15% PEG 4000, 0.15 M (NH4)2SO4,  0.1  M MES buffer  pH 6.  A dataset  at  2.35  Å was  
collected which was processed in space group C2 using XDS (Study III, Table 1).  
The complex structure was solved by molecular replacement using the previous GDNF-
GFR?1  structure  (2V5E)  as  a  search  model.  The  asymmetric  unit  contains  two  GDNF-
GFR?1 heterodimers (chains A&B, C&D), each forming an independent symmetric 
heterotetramer around the two unique crystallographic two-fold axes. The two new 
GDNF2-GFR?12 complexes  are  almost  identical  (Study  III),  and  have  almost  the  same  
bend angle of 158?. 
The new GDNF complex (3FUB) is very similar to the previous complex structure 
(heterodimer RMSD of 1.9 Å for 280 C?). The important difference between the two 
GDNF2-GFR?12 complexes (2V5E & 3FUB) is in the GDNF. The GDNF heel is rotated 
by about 20? in the heterodimer superposition (Study III, Figure 4), which is accompanied 
by a rotation of 20? of the right hand heterodimer, viewed down the two-fold axis (Figure 
4.8). Nonetheless, the bend angle in the GDNFs and the separation between the two 
putative RET binding surfaces is almost identical to that in the previous structure (2V5E). 
The GDNF structural changes thus do not considerably affect the positioning of the RETs 
with respect to each other on the inside of the membrane. On the other hand, superposition 
of the ARTN2-GFR?32 complex with the new GDNF2-GFR?12 complex (code 3FUB) 
results in similar differences in the GFL bend angle as with 2V5E.  
So far five GDNF crystal structures have been determined both unbound and with 
coreceptor bound. Each GDNF2 has a different bend angle varying from 146? to 168? 
(Figure 1.2B). On the other hand, the six ARTN structures are more rigid; the bend angle 
in the homodimeric structures varies from 201?-206?. Therefore it appears that GDNF2 has 
more bend angle flexibility than ARTN2. However, comparison of the two GDNF2-
GFR?12 complexes suggests that the structural variation in GDNF2 (Study III, Figure 6) 
do not affect the heterotetrameric arrangement of the complex, but the larger difference 
between GDNF2 and ARTN2 do (Figure 4.7C). In addition, the structural differences 
between the GDNF- and ARTN-coreceptor complexes do not appear to be due to 
crystallization artefacts. Thus comparison of previous GFL2-GFR?2 complexes (2V5E and 
2GH0) with the new GDNF2-GFR?12 complex (3FUB) supports our proposal about the 
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role of bend angle in GDNF signalling (see section 4.1.3.2). What causes bend angle 
differences among GFLs and what makes GDNF2 more flexible? 
 
Figure 4.8 Comparison between the two GDNF2-GFR?12 complexes. A) & B) Superposition of 
the GDNF2-GFR?12 complexes (2V5E & 3FUB). The left-hand heterodimer was superimposed to 
show the differences in the right-hand heterodimer. The two-fold axis in the two heterotetramers is 
thus in a slightly different position in each structure; the one shown is for 3FUB. The bend in the 
quaternary  structure  of  the  GDNF2-GFR?12 complex  is  the  same  in  both  structures.  Figure  B  is  
rotated 90? from Figure A about the horizontal axis. The red arrow represents the direction of 
motion between the two right-hand GFR?1s. Reprinted with permission from Acta Cryst. sect. F 
(Study III) copyrights 2009. 
 
Molecular basis for GFL variation 
The head-to-tail homodimer structure of the GFLs is formed by the packing of the heel 
against the finger domain of the other monomer. In the 11 unique ARTN and GDNF 
structures known so far, ARTN2 buries approximately 800 Å2 more surface area at the 
homodimer interface. As can be seen (Figure 1.2), ARTN fingers are more curved, which 
allow ARTN2 to bury more surface area at the homodimer interface. In addition, the 
curvature affects the hinge angle, which subsequently influences the bend angle. Thus, 
both the observed GDNF flexibility and the variation in the ligand bend angle are because 
the GDNF fingers are less curved.  
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The residues at the homodimer interface form the molecular basis for ligand bend angle 
and its flexibility. At the homodimer interface, the substantial change of I82GDNF?SARTN 
in the heel is accompanied by a complementary change of H126GDNF?LARTN in the finger 
domain of the other monomer. The bulkier Ile82 in GDNF2 pushes His126 backwards, 
which in turn pushes Leu111 of strand ?3b (Study III, Figure 7). On the other hand, the 
analogous residues S82, V111 and L126 (GDNF numbering) at the ARTN2 interface are 
less bulky (Figure 4.6C); their interactions bring the fingers closer to the heel (Study III, 
Figure 7). The same applies to L48GDNF?VARTN change at finger 1. These changes bring 
curvature in the ARTN fingers, bringing the fingers closer to the heel than in GDNF 
(Figure 4.6). It thus increases the bend angle between the ARTN monomer fingers.  
NRTN should have an ARTN-like structure, as three (V48, V111, L126) of the four 
residues mentioned above are similar to ARTN (Figure 4.6C). The only significant 
difference between NRTN and ARTN is the residue at position 82, which is Ser in ARTN 
and Gly in NRTN; this should increase, not decrease, the level of curvature.  Therefore, 
NRTN appears to be rigid and essentially flat, so it probably shows ARTN-like, not 
GDNF-like, MAPK activation. 
 Since loop 'L3' in GDNF (Figure 1.2A) is disordered or has high B-factors in all of the 
GDNF-containing crystal structures (Study III, Table 3), it may provide flexibility to the 
GDNF2 structure. On the other hand, the post-helix loop L3 of ARTN (Study III, Figure 1 
and 8) is more ordered in all the six ARTN structures (Silvian et al., 2006; Wang et al., 
2006). The pre-helix L2 region in ARTN is positively charged 73RRARS77 and forms a 310 
helix, while the GDNF 73DAAET77 does not (Study III, Figure 1). This change in the pre-
helix region appears to provide a different relative orientation of finger 1 with respect to 
the heel, which affects the hinge angle. Thus, in addition to the heel region, the pre-helix 
and the post-helix loops of the GFLs also seem to influence the bend angle. 
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4.2 Structural studies of MANF and CDNF 
MANF and CDNF are two newly discovered neurotrophic factors. There are no structures 
for  these  proteins.  In  an  attempt  to  unravel  the  molecular  basis  of  MANF/CDNF  
signalling,  I  solved  the  crystal  structures  of  MANF and CDNF.  The  results  described  in  
this section are based on Study II. 
4.2.1  The crystal structure of MANF and CDNF 
Mature human MANF (amino acids 1-158) was expressed in Escherichia coli Origami 
(DE3) cells as a His-tagged fusion protein (Peränen et al., 1996). It was purified by Ni2+-
affinity, ion exchange and size-exclusion chromatography. MANF crystals grew over a 
reservoir solution of 100 mM Na-cacodylate  buffer,  pH  6.5,  0.2  M  MgAc2 and 12-18% 
PEG 8000. Three datasets were collected; native data diffracted to 3.0 Å, sulphur-SAD to 
2.8 Å, and Hg-derivative to 4.0 Å (Study II, Table 1). The crystals belong to space group 
P61.  
Recombinant human CDNF (amino-acids 1-167) was expressed in Sf9 insect cells and 
purified as described (Lindholm et al., 2007). A proteolytic N-terminal fragment that co-
purified with the full-length CDNF was, after tag-removal, purified to high homogeneity 
by gel filtration using a Superdex 200 (GE Healthcare) column. The fragment was 
assigned as CDNF-?C, which crystallized over a reservoir solution of 100 mM NaAc, pH 
4.6, 0.2 M NH4Ac and 25-30% (w/v) MME-PEG 2000. A native dataset, which diffracted 
to 1.6 Å, was collected. The crystals belong to space group P21 with  two molecules  per  
asymmetric unit. For selenomethionine (SeMet) labelling in insect cells, the CDNF-?C 
expression protocol was modified according to Leppänen et al. (2004). MAD data were 
collected from a SeMet-substituted CDNF-?C crystal. Using SHELX (Schneider and 
Sheldrick, 2002), six selenium sites were identified and refined to calculate phases for the 
MAD data. The final model contained two identical molecules of CDNF-?C 9-105 in the 
asymmetric unit (RMSD 0.25 Å for all C?). The structure was refined using native data to 
a final R-factor of 20.9% (Rfree 24%).  
For MANF structure solution, position of three Hg atoms were determined and refined by 
using the SHELX C/D/E programs in HKL2MAP (Schneider and Sheldrick, 2002). After 
improving and extending the phases using DM (Collaborative Computational Project, 
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Number 4, 1994), a partial model was built from Hg-phased electron density map. Finally, 
the CDNF-?C structure was used as a search model to solve the structure of MANF. The 
anomalous map from Hg-phases and S-SAD structure factors identified four disulphide 
bridges, three in the N-terminus and the fourth one in the C-terminus. The final MANF 
structure was refined at 2.8 Å resolution using S-SAD data to a crystallographic R-factor 
of 28.0% (Rfree 30.5%). 
4.2.1.1 The closed saposin fold of N-termini of MANF and CDNF  
The N-termini of MANF (MANF-N1-95) and CDNF (CDNF-?C9-105) are essentially the 
same (RMSD 0.89 Å for 86 C?), consisting of five ?-helices (?1-?5) followed by a turn of 
310 helix (Figure 4.9A, 4.9B and 4.9C). The structural fold of MANF-N and CDNF-?C is 
identical to the ‘closed’ saposin-like fold (Figure 4.9B-E), and the spacing between the six 
cysteines in their sequences is identical to that in the 80 residues long SAPLIP domain 
(Figure 4.9A). The closest structural homologs of MANF-N and CDNF-?C are granulysin 
(Anderson et al., 2003) and NK-lysin (Liepinsh et al., 1997), which are membrane-lytic 
SAPLIPs. The RMSDs of superposition for CDNF-?C and MANF-N upon granulysin are 
3.5 Å and 3.0 Å for 69 and 70 C?-atoms, respectively, out of a total of 74 C?-atoms. 
Compared to other SAPLIPs, granulysin sequence has five cysteines, which can form only 
two disulphide bridges. The SAPLIP domain in most proteins has low sequence identity 
??17%) to saposins, and so do MANF and CDNF. Thus MANF and CDNF are distantly 
related to saposins (Figure 4.10).  
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Figure 4.9 Aligned sequences of MANF,  CDNF  and  related  SAPLIPs,  and  their  structures  in  
‘open’ and ‘closed’ conformations. A) Structure based sequence alignment of the N-termini of 
MANF and CDNF with saposin A, B, C, D, and granulysin and NK-lysin. B) Cartoon 
representation of MANF colour coded from blue to red. Disulphide bridges are shown in sticks 
with carbon in magenta and sulphur in yellow. The flexible C-terminus is composed of a 
connecting loop and two helices. An arrow marks the position of the fourth disulphide bridge. C) 
CDNF-?C in the same orientation, colour and cartoon scheme as Figure B. D) & E) Granulysin 
and saposin C showing the ‘closed’ saposin fold as a rainbow. F) The "domain swapped" saposin 
C homodimer. One monomer is in cartoon (yellow), and the other one is shown in electrostatic 
surface representation. Colour scheme in surface representation: blue, positive; red, negative and 
white, hydrophobic residues.  
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Figure 4.10 Phylogenetic tree for SAPLIP family including MANF and CDNF. 
 
4.2.1.2 The C-terminus of MANF and CDNF 
The C-terminus of MANF was disordered in the crystal structure, and I could only build 
polyalanine model for residues 95-137 (Figure 4.9B). Residues 138-158 are not visible at 
all. It is consistent with the unstructured regions indicated by DisEMBL (Linding et al., 
2003). The MANF C-terminus consists of a loop from 95 to 111 followed by two parallel 
helices (?6 and ?7) connected by a loop from residues 123 to 130. The C-terminus, 
therefore, can adopt different conformations, and in the structure in the crystal is stabilized 
by crystal contacts.  
Recent studies have shown cytoprotective role of MANF and presumably CDNF using a 
variety of ER stress models (see section 1.4.3). ER stress results in accumulation of 
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unfolded proteins, which induces UPR. UPR reduces ER stress by enhancing the protein 
folding capacity and degradation of misfolded proteins. Thiol/disulphide oxidoreductases, 
the CXXC motif containing proteins, increase protein folding by catalyzing the formation 
of intramolecular disulphide bonds. These proteins include thioredoxins, like protein 
disulphide isomerases (PDIs), which function in the ER (Ellgaard and Ruddock, 2005). 
The CXXC motif containing proteins are usually involved in reduction, oxidation and 
isomerisation reactions that are necessary for proper disulphide bond formation of target 
proteins in the ER (Horibe et al., 2004). The CXXC motif may also bind metal ions in 
metal-binding proteins, including PDI (Narindrasorasak et al., 2003).  
MANF and CDNF contain two CXXC motifs in the N- and C-termini (Figure 1.5).  The 
cysteines C9 and C6 in the N-terminus motif form disulphide bridges with the cysteines on 
helices  ?5  and  310, respectively, as in other SAPLIPs. The second 127CXXC130 motif 
(MANF numbering) forms an internal disulphide bridge in the MANF structure (Figure 
4.9B). Like oxidoreductases, the C-terminal CXXC motif of MANF may also be involved 
in protein folding, which may explain its cytoprotective role in the ER. 
 
4.2.2  Functional implications from MANF and CDNF structures 
4.2.2.1 Interaction with lipid or membrane  
Interestingly, SAPLIPs have a characteristic ability to interact with membranes or lipids 
(Bruhn, 2005). Saposin C was shown to interact with lipids through the positively charged 
residues, which are thought to interact with negatively charged lipid headgroups to initiate 
membrane binding (Liu et al., 2005). Furthermore other SAPLIPs, such as NK-lysin and 
granulysin, also have positively charged residues on the surface, which are also indicated 
to interact with the negatively charged lipid headgroups in the membrane (Miteva et al., 
1999; Sánchez-Barrena et al., 2003). In a similar way, the SAPLIP domain of MANF and 
CDNF has conserved positively charged residues on the surface that are located in two 
adjacent regions. These include R44, K46, R49 and K96 (MANF numbering), which lie 
on ?3 and ?5 within one region. Other region oriented approximately 90° to the first 
contain K70, K80, K84, K86 and K87 (Figure 4.11A & 4.11B). This suggests that, like 
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saposins and SAPLIPs, the conserved positively charged residues of MANF and CDNF 
might bind lipids.  
 
Figure 4.11 Sequence alignment and conserved surfaces of the N-terminal domain. A) Structure-
based sequence alignment between the N-terminus of human-, rat- and Dm-MANF, and human 
CDNF, with secondary structure elements indicated above the alignment. Blue: completely 
conserved in the individual families (>80% identity); semi-conserved (60-80% identity), black; 
non-conserved (<60% identity), red. MANF sequence numbering is shown above and CDNF 
numbering below. Last line: consensus alignment for the entire MANF/CDNF family: conserved 
in blue (uppercase), semi-conserved in black (lowercase); non-conserved as red dots. The most 
non-conserved residues between Dm-MANF and human-CDNF are boxed in orange. Residue 70 is 
strictly conserved as Lys in MANF, while it is conserved as Arg in CDNFs (Figure 1.5). It is also 
boxed in orange, as this change may also contribute to functional differences between MANF and 
CDNF. Conserved positively charged residues are bolded. Dm, Drosophila melanogaster. B) 
MANF-N surface coloured by conservation: Blue, conserved; brown, semi-conserved; salmon, 
non-conserved. The similar residues R44/K, D59/E, A60/S and K96/R are shown in cyan. Left: the 
most conserved surface of MANF-N. Right: the most non-conserved surface. It is related to the left 
image by a rotation of 180° about the vertical axis in the picture. Conserved positively charged 
surface residues are labelled in black and white, while the positions of the three biggest differences 
between MANF and CDNF (I10K, E79M and K88L) are labelled in magenta. Reprinted with 
permission from PEDS (Study II) copyrights 2009. 
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Initial experiments indicated that MANF and CDNF also interact with lipids, which may 
be crucial for the activity of CDNF and MANF (Hongxia Zhao and Mart Saarma personal 
communication). However, unlike granulysin and NK-lysin, MANF and CDNF do not 
seem to disrupt the target membranes, as they do not induce cell death (Lindholm and 
Saarma, unpublished). 
4.2.2.2 Oligomerisation  
Oligomerisation is common to saposins and SAPLIPs, which can be induced by its 
interaction with lipids or in response to pH changes. Interaction of lipids with saposin B 
opens its folded leaf structure to form a dimer (Figure 1.6B). The solution structure of 
saposin C also opens its hydrophobic core in the presence of sodium dodecyl sulphate 
(Hawkins et al., 2005). At low pH (4.8) or in the presence of detergent, saposins A and C 
form dimers and trimers in solution (Ahn et al., 2003). The crystal structure of saposin C 
at pH 4 revealed another open conformation where it formed a domain-swapped 
homodimer (Figure 4.9F), but saposin D at pH 6 crystallized as a dimer in the closed 
conformation (Rossmann et al., 2008). Interestingly, the crystal structure of CDNF-?C, in 
the closed conformation, contained a dimer in the asymmetric unit at pH 4.6, while MANF 
crystallized as a monomer at neutral pH. Lipid binding or pH changes may also induce 
dimerization of CDNF and MANF.  
4.2.3  Comparison between MANF and CDNF 
MANF and CDNF have shown similar expression in mouse tissues (Lindholm et al., 
2007; 2008). Like GDNF (Lin et al., 1993), both MANF (Voutilainen et al., 2009) and 
CDNF (Lindholm et al., 2007) protect and repair midbrain dopaminergic neurons in vivo 
in a rat 6-OHDA model of PD. Recently, MANF was shown to be neuroprotective against 
cerebral ischemia (Airavaara et al., 2009). Though sharing similar biological functions, 
MANF and CDNF show no sequence or structural homology to other neurotrophic factors 
such as GDNF and BDNF. 
The only ortholog in invertebrates, which is more related to vertebrate MANF than CDNF 
(Palgi et al., 2009), suggests that the two paralogs MANF and CDNF in vertebrates might 
be the result of gene duplication event during evolution. In gene knockout experiments, 
only human MANF, not CDNF, rescues the Drosophila MANF gene knockout lethality, 
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suggesting different functions governed by both the proteins, although both shared high 
sequence and structural similarity (Palgi et al., 2009). This functional difference between 
human-MANF and CDNF might be due to surface residues that are similar or identical in 
human- and Dm-MANF but different in human-CDNF. There are three such regions: K38, 
R41 on helix ?2 (S, L in CDNF); L1, I10, E79 on helix ?1 and ?5 (G, K, M in CDNF); 
and N66, K70 and K88 on helix ?4 and ?5 (S, R and L) (Figure 4.11). Of these, the strictly 
conserved residues L1, N66, K70, E79 and K88 in MANFs appear to be more important 
than the less well conserved I10, K38 and R41 (Figure 4.11A). Therefore, the changes 
MANFL1?GCDNF, MANFN66?SCDNF, MANFK70?RCDNF, MANFE79?MCDNF and 
MANFK88?LCDNF probably cause the functional differences between CDNF and MANF. 
Most  significant  of  these  are  the  E79?M and K88?L  changes,  which  are  non-
conservative changes next to the conserved positive region that is indicated to be involved 
in membrane binding. 
4.2.4  Bifunctional role of MANF and CDNF 
Recent studies on MANF and CDNF suggest that they have dual role: as extracellular 
neurotrophic factors and as ER resident cytoprotective proteins. MANF (Petrova et al., 
2003; Voutilainen et al., 2009) and CDNF (Lindholm et al., 2007) promote the survival of 
midbrain dopaminergic neurons, and MANF is also cytoprotective against ER stress 
induced cell death (Apostolou et al., 2008; Tadimalla et al., 2008).  The structures of 
MANF  and  CDNF  reveal  a  saposin  fold,  and  these  proteins  are  the  first  SAPLIPs  with  
neuroprotective and neurorestorative activities, along with a role in the ER stress response. 
Since the characteristic feature of saposins and SAPLIPs is to bind lipids or membranes 
via positively charged residues on their surface (Bruhn, 2005), it is possible that the 
conserved Lys and Arg residues on the MANF/CDNF surface bind negatively charged 
lipid headgroups in the membrane. In addition, saposin C and prosaposin have been 
indicated to have neurotrophic activities (Kotani et al., 1996; Liu et al., 2001). Secreted 
MANF and CDNF may thus interact with membrane lipids or with a transmembrane (lipo) 
receptor through its N-terminus SAPLIP domain but their mode of action is unclear. Initial 
experiments have shown that MANF and CDNF indeed interact with lipids. 
Oxidoreductases, like PDIs, contain CXXC motifs and function in the ER (Collet et al., 
2003; Horibe et al., 2004). The crystal structure of MANF C-terminus, which also contain 
CXXC  motif,  supports  the  idea  of  MANF  (and  CDNF)  as  an  anti  ER  stress  protein.  
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MANF and CDNF may facilitate protein folding in the ER by proper disulphide bond 
formation, thus reducing the ER stress caused by unfolded or incorrectly folded proteins.  
On the other hand, cytoprotection and neurotrophic effects may be related. In vitro studies 
suggest that 6-OHDA toxicity results in ER stress (Silva et al., 2005). It is possible that 
neurotrophic activity of CDNF (Lindholm et al., 2007) or MANF (Voutilainen et al., 
2009) on adult rat 6-OHDA model of PD is due to reduction in ER stress. Although initial 
experiments have failed to detect oxidoreductase activity (Mizobuchi et al., 2007), further 
characterization of these proteins is needed to demonstrate their oxidoreductase or metal 
binding activities and their cellular targets. 
 
 69 
5.  CONCLUSIONS 
Here I solved the crystal structure of the GDNF2-GFR?12 complex, which is the first step 
in GDNF2-GFR?12-RET2 signalling. The complex structure is formed by the interaction of 
GDNF fingers with the triangular helix spiral within D2 of GFR?1. The key interaction at 
the interface is the ion triple ArgGFR?-GluGFL-ArgGFR?. The mutations N162AGFR?1 and 
I175GGFR?1 at the ligand-binding interface abolish RET phosphorylation. These residues, 
and the previously identified Y120GDNF and L114GDNF, are non-conserved and determine 
the specificity between GFL-GFR? complexes (Study I). 
The bend angle difference between GDNF and ARTN induces a large structural change in 
the GDNF2-GFR?12 and  ARTN2-GFR?32 complexes.  It  appears  to  form  the  basis  of  
varied signalling between different GFLs (Study I). The second crystal structure of the 
GDNF2-GFR?12 complex has a similar bend angle to the first one, which suggests that the 
difference between the GDNF2-GFR?12 and ARTN-GFR?32 complexes are not due to 
crystallographic artefacts (Study III). 
The binding of GFR?1 to the heparin column suggests that GFR?1 has a heparin-binding 
site.  In the GDNF2-GFR?12 complex structure (Study I), D2 of GFR?1 binds the heparin 
mimic SOS. Modelling of pentasaccharide on SOS in the structure of the complex 
suggests how heparin binds GFR?1. In addition, mutagenesis data suggest that the heparin 
binding surface of GFR?1 is involved in RET binding too. These new insights into the 
heparin and RET binding can explain how exogenous heparin could inhibit RET 
phosphorylation. Furthermore, the arrangement in the crystal structure suggests that cell 
surface heparan sulphate chains may link GDNF2-GFR?12 complexes in trans, which 
induces synapses (Study I). 
In addition, I solved the crystal structures of two new evolutionarily conserved 
neurotrophic factors, MANF and CDNF, which support the survival of dopaminergic 
neurons (Study II). The structures provide a beginning towards the identification of their 
signalling  mechanism.  Both  structures  have  a  completely  different  fold  from  any  of  the  
previously known growth factor superfamilies. However, the N-terminal domains of 
MANF and CDNF are SAPLIPs. Like lipid-binding SAPLIPs, the conserved Lys and 
Args  on  the  MANF  and  CDNF  surface  in  the  N-terminal  domain  may  interact  with  
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phospholipids. The MANF structure suggests that the CXXC motif in the natively 
unfolded C-terminus forms a disulphide bridge. As CXXC motifs are common in protein 
disulphide isomerases or reductases, the C-terminus of MANF may thus be involved in 
oxidative protein folding, which explains its function in the ER. Thus structural studies of 
MANF and CDNF indicate an explanation for this bifunctional role: the N-terminal 
domain may be responsible for its neurotrophic activity and the C-terminal domain may 
function in the ER. Finally, the highly similar MANF and CDNF surfaces of the N-
terminal domain indicates three positions in the sequence (10, 79 and 88), which are 
conserved in human and Drosophila MANF but non-conserved in human-CDNF. Here 
these residues are proposed to account for the functional difference between MANF and 
CDNF in rescue experiments in Drosophila MANF gene knockouts. 
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